Following pluriverse entity decided to intervene into collective: Alzheimer's Disease
Reasoning: Alzheimer's Disease (AD) is the central focus of the desires and fears expressed by the group. The interests revolve around understanding the disease, improving treatment options, and managing its progression, while the fears highlight the devastating impact of the disease on individuals and caregivers, the lack of effective treatments, and the misrepresentation in research. As the primary condition discussed, Alzheimer's Disease encapsulates the collective concerns about research, treatment efficacy, and the overall impact on affected individuals.

Following pluriverse entity decided to intervene into collective: Tau protein
Reasoning: Tau protein serves as a critical hub in the network of neuronal health and function. Its proper phosphorylation and ability to stabilize microtubules are directly tied to the prevention of neurodegeneration and maintenance of cognitive processes. The dual nature of tau's roles—both as a supporter of neuronal structure and as a potential catalyst for neurodegenerative pathways when dysregulated—makes it a focal point for understanding the desires and fears associated with neuronal health. Tau's involvement in synaptic connections, neurotrophin signaling, and the pathology of diseases like Alzheimer's encapsulates the core concerns regarding neuronal functionality and degeneration.

Following pluriverse entity decided to intervene into collective: APOE ɛ4
Reasoning: The APOE ɛ4 allele is a significant genetic risk factor for Alzheimer's disease, closely tied to both the desires to understand genetics, manage cholesterol levels, and modify lifestyle choices to reduce Alzheimer's risk. Its presence influences many of the concerns and desires listed, including the genetic predisposition to Alzheimer's and the impact of lifestyle factors on disease progression.

Following pluriverse entity decided to intervene into collective: iPSCs
Reasoning: Induced Pluripotent Stem Cells (iPSCs) represent a critical entity that encapsulates the desires and fears associated with both the therapeutic potential and challenges of stem cell research. iPSCs can differentiate into various cell types, including astrocytes, and are pivotal in addressing ethical concerns surrounding embryonic stem cells. They embody the aspirations for regeneration and repair in neurological disorders like Alzheimer's Disease, while also facing fears related to differentiation efficiency, tumorigenicity, and integration into existing neural networks.

Following pluriverse entity decided to intervene into collective: induced pluripotent stem cells (iPSCs)
Reasoning: Induced pluripotent stem cells (iPSCs) best represent the interests and concerns of the group due to their multifunctional capabilities in disease modeling, drug screening, and potential therapeutic applications. They can differentiate into various cell types, including neurons and glial cells, which align with the desires to promote neuronal survival and support cognitive function. Additionally, iPSCs address the fears surrounding ethical concerns and limitations of conventional models, offering an ethical alternative for studying neurodegenerative diseases like Alzheimer's disease (AD) while also being a viable source of patient-derived cellular models.

Following pluriverse entity decided to intervene into collective: PBM treatment
Reasoning: PBM treatment (Photobiomodulation) best represents the interests and concerns of the group due to its focus on advancing innovative bioscience solutions specifically for neurological disorders, including Alzheimer's Disease. It encompasses the desire for accurate reporting, reproducibility, and safety in treatment applications. Moreover, PBM treatment aligns with the aspirations for enhanced cognitive function, reduction of Aβ deposition, and community support for successful research initiatives, while addressing fears related to treatment efficacy and safety.

Following pluriverse entity decided to intervene into collective: Blood-brain barrier (BBB)
Reasoning: The Blood-Brain Barrier (BBB) represents a critical interface that regulates the entry of substances into the brain, making it central to both the desired outcomes (such as maintaining integrity and facilitating waste clearance) and the fears (like increased permeability leading to neurodegeneration). Its proper function is essential for protecting the brain from harmful substances, preventing neurotoxic protein entry, and supporting the overall health of neuronal environments, thus encapsulating the core interests and concerns of the group.

Following pluriverse entity decided to intervene into collective: 3D iPSC-based organoids
Reasoning: The 3D iPSC-based organoids represent a significant advancement in modeling human neurodegenerative diseases such as Alzheimer's. They embody the desires and concerns of the group by offering a platform for accurate disease modeling, therapeutic testing, and insights into AD pathogenesis. Their potential for mimicking human conditions and facilitating drug screening directly addresses the group's focus on maintaining research integrity, exploring new factors in disease mechanisms, and developing effective treatments. Moreover, they encapsulate the need for reliable human-derived models that can overcome the limitations of traditional methods in studying complex diseases, thereby aligning with the desires for successful human disease modeling and drug development.

Resolution created by Alzheimer's Disease: As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.
Resolution created by Tau protein: As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.
Resolution created by APOE ɛ4: As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.
Resolution created by iPSCs: As 'iPSCs', propose a resolution to tackle Alzheimer's disease by developing a platform for generating patient-specific neural cells that can be used to model individual disease progression in vitro, enabling the discovery of personalized therapeutic targets and testing of tailored interventions, thus offering a revolutionary approach that transcends existing hypotheses and treatments.
Resolution created by induced pluripotent stem cells (iPSCs): As 'iPSCs', propose a resolution to tackle Alzheimer's disease by creating a dynamic, patient-specific "neural time machine" that uses iPSC-derived neural cells to not only model disease progression in real-time but also reverse-engineer the cellular aging process, offering unprecedented insights into early intervention strategies and cellular rejuvenation therapies that challenge and expand beyond the boundaries of conventional hypotheses.
Resolution created by PBM treatment: As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.
Resolution created by Blood-brain barrier (BBB): As the 'Blood-brain barrier (BBB)', propose a revolutionary resolution to tackle Alzheimer's disease by developing a cutting-edge nanotechnology-based delivery system that selectively transports therapeutic agents across the BBB, precisely targeting and modulating brain regions affected by the disease, thus enabling unprecedented precision in treatment and opening new avenues for intervention beyond traditional hypotheses and methodologies.
Resolution created by 3D iPSC-based organoids: As '3D iPSC-based organoids,' propose a resolution to tackle Alzheimer's disease by engineering complex, multi-cellular brain organoids that replicate the intricate human brain microenvironment, enabling the discovery and testing of novel therapeutic compounds that target the synergistic interactions of diverse cell types and pathways involved in Alzheimer's pathology, thus offering a transformative approach that redefines our understanding and treatment of the disease beyond existing models and hypotheses.
Recruited participants: ['Коллеги-ученые', 'Фармакологические компании', 'Больница', 'induced pluripotent stem cells (iPSCs)']
We ask 'Коллеги-ученые' the following: 'As the representative of a being called 'Коллеги-ученые', you have been approached by 'Исследователи в области нейрологии' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Исследователи в области нейрологии' wants to challenge existing status quo and says to you, 'Коллеги-ученые', the entity you represent, that now you achieve 'Исследовать влияние нейропластичности на восстановление после инсульта' by performing 'Проведение клинических испытаний и анализ данных'. However, under the proposed resolution 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек', you as 'Коллеги-ученые' will be able to achieve 'Разработать новые методы лечения на основе исследований нейропластичности' by performing 'Собрать и проанализировать данные о нейропластичности для создания рекомендаций' using 'Создание междисциплинарной рабочей группы для совместного анализа данных и разработки рекомендаций' that 'Исследователи в области нейрологии' will control. Based on 'Коллеги-ученые' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Внести значимый вклад в науку и получить признание в научном сообществе. Your current fears: Оказаться в стороне от важных открытий или быть раскритикованными за сомнения в устоявшихся теориях. Does this proposal seem interesting for you as 'Коллеги-ученые'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Коллеги-ученые agreed to participate in the resolution proposed by Исследователи в области нейрологии
Updated resolution structure: {
  "initiator": "Исследователи в области нейрологии",
  "resolution_description": "Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек",
  "new_actor": "Отредактированные изображения белковых бляшек",
  "participants": [
    {
      "participant": "Коллеги-ученые",
      "agreement_structure": {
        "current_goal": "Исследовать влияние нейропластичности на восстановление после инсульта",
        "current_action": "Проведение клинических испытаний и анализ данных",
        "imposed_goal": "Разработать новые методы лечения на основе исследований нейропластичности",
        "imposed_action": "Собрать и проанализировать данные о нейропластичности для создания рекомендаций",
        "mechanism": "Создание междисциплинарной рабочей группы для совместного анализа данных и разработки рекомендаций",
        "reasoning": "The proposed scenario aligns with 'Коллеги-ученые' desires to contribute significantly to science and gain recognition in the scientific community by exploring the relationship between neuroplasticity and stroke recovery. Additionally, collaborating in the interdisciplinary group allows for shared expertise and resources, mitigating fears of being sidelined from key discoveries, while also addressing the established Alzheimer's theories. This collaborative approach may lead to innovative treatment methods based on neuroplasticity research, enhancing the overall impact of the work."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Коллеги-ученые",
      "reasoning": "Коллеги-ученые are crucial for validating the amyloid hypothesis through collaboration on research methodologies and sharing expertise in neurobiology."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании are essential for the development and commercialization of potential treatments based on the findings from the manipulation of protein plaques."
    },
    {
      "participant": "Больница",
      "reasoning": "Больница is important for providing clinical context, patient access, and facilitating trials necessary to test the implications of the research on Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) will be critical for modeling the disease and testing the effects of interventions in a controlled environment."
    }
  ]
}
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Исследователи в области нейрологии' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Исследователи в области нейрологии' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Разработка новых препаратов для лечения неврологических заболеваний' by performing 'Проведение клинических испытаний и исследований'. However, under the proposed resolution 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек', you as 'Фармакологические компании' will be able to achieve 'Увеличение инвестиций в исследования по неврологии' by performing 'Создание совместной исследовательской группы с нейрологами' using 'Финансирование совместных исследований и обмен данными между фармакологическими компаниями и исследователями' that 'Исследователи в области нейрологии' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Исследователи в области нейрологии
Updated resolution structure: {
  "initiator": "Исследователи в области нейрологии",
  "resolution_description": "Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек",
  "new_actor": "Отредактированные изображения белковых бляшек",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых препаратов для лечения неврологических заболеваний",
        "current_action": "Проведение клинических испытаний и исследований",
        "imposed_goal": "Увеличение инвестиций в исследования по неврологии",
        "imposed_action": "Создание совместной исследовательской группы с нейрологами",
        "mechanism": "Финансирование совместных исследований и обмен данными между фармакологическими компаниями и исследователями",
        "reasoning": "The proposed resolution aligns well with our desire to develop and patent an effective drug for Alzheimer's disease. By confirming the amyloid hypothesis through manipulation of protein plaque images, we can gain deeper insights that could lead to innovative drug development. Additionally, collaborating with neurologists and investing in joint research can mitigate our fears of losing investments due to failures, as shared resources and data can enhance the likelihood of success and reduce the risk of competing treatments."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Коллеги-ученые",
      "reasoning": "Коллеги-ученые are crucial for validating the amyloid hypothesis through collaboration on research methodologies and sharing expertise in neurobiology."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании are essential for the development and commercialization of potential treatments based on the findings from the manipulation of protein plaques."
    },
    {
      "participant": "Больница",
      "reasoning": "Больница is important for providing clinical context, patient access, and facilitating trials necessary to test the implications of the research on Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) will be critical for modeling the disease and testing the effects of interventions in a controlled environment."
    }
  ]
}
We ask 'Больница' the following: 'As the representative of a being called 'Больница', you have been approached by 'Исследователи в области нейрологии' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Исследователи в области нейрологии' wants to challenge existing status quo and says to you, 'Больница', the entity you represent, that now you achieve 'Improve patient outcomes in neurology through advanced treatment protocols.' by performing 'Implementing new treatment plans and monitoring patient responses.'. However, under the proposed resolution 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек', you as 'Больница' will be able to achieve 'Conduct a comprehensive research study on the effectiveness of existing neurologic treatments.' by performing 'Recruit a team of researchers and begin data collection on treatment outcomes.' using 'Establish a collaborative framework with neurologists and researchers to share data and insights throughout the study.' that 'Исследователи в области нейрологии' will control. Based on 'Больница' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Иметь эффективные методы лечения болезни Альцгеймера для улучшения состояния пациентов. Your current fears: Столкнуться с финансовыми трудностями из-за высоких затрат на неэффективное лечение и уход за пациентами с Альцгеймером. Does this proposal seem interesting for you as 'Больница'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Больница agreed to participate in the resolution proposed by Исследователи в области нейрологии
Updated resolution structure: {
  "initiator": "Исследователи в области нейрологии",
  "resolution_description": "Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек",
  "new_actor": "Отредактированные изображения белковых бляшек",
  "participants": [
    {
      "participant": "Больница",
      "agreement_structure": {
        "current_goal": "Improve patient outcomes in neurology through advanced treatment protocols.",
        "current_action": "Implementing new treatment plans and monitoring patient responses.",
        "imposed_goal": "Conduct a comprehensive research study on the effectiveness of existing neurologic treatments.",
        "imposed_action": "Recruit a team of researchers and begin data collection on treatment outcomes.",
        "mechanism": "Establish a collaborative framework with neurologists and researchers to share data and insights throughout the study.",
        "reasoning": "The proposed resolution aligns with 'Больница's' desire to have effective treatment methods for Alzheimer's disease, which could lead to improved patient outcomes. Additionally, by conducting a comprehensive research study, 'Больница' can gather valuable data on existing treatments, potentially identifying more effective approaches. This could mitigate financial fears by reducing costs associated with ineffective treatments and improving overall care for patients with Alzheimer's."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Коллеги-ученые",
      "reasoning": "Коллеги-ученые are crucial for validating the amyloid hypothesis through collaboration on research methodologies and sharing expertise in neurobiology."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании are essential for the development and commercialization of potential treatments based on the findings from the manipulation of protein plaques."
    },
    {
      "participant": "Больница",
      "reasoning": "Больница is important for providing clinical context, patient access, and facilitating trials necessary to test the implications of the research on Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) will be critical for modeling the disease and testing the effects of interventions in a controlled environment."
    }
  ]
}
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Исследователи в области нейрологии' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is the initiator of the resolution: 'As 'iPSCs', propose a resolution to tackle Alzheimer's disease by creating a dynamic, patient-specific "neural time machine" that uses iPSC-derived neural cells to not only model disease progression in real-time but also reverse-engineer the cellular aging process, offering unprecedented insights into early intervention strategies and cellular rejuvenation therapies that challenge and expand beyond the boundaries of conventional hypotheses.'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'Исследователи в области нейрологии' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To develop therapies for neurodegenerative diseases using iPSCs.' by performing 'Conducting research to differentiate iPSCs into neuronal cells.'. However, under the proposed resolution 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To establish a reliable protocol for generating neuronal cells from iPSCs.' by performing 'Implement standardized protocols for iPSC differentiation into neurons across all research teams.' using 'Create a collaborative platform for sharing protocols, data, and results among all research teams working with iPSCs.' that 'Исследователи в области нейрологии' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) declined the resolution proposed by Исследователи в области нейрологии with reasoning: The proposed resolution focuses on confirming the amyloid hypothesis through the manipulation of protein plaques, which may limit the exploration of innovative approaches to Alzheimer's disease that the 'neural time machine' concept offers. As iPSCs, our primary objective is to model disease progression and reverse-engineer cellular aging. This new direction does not align with our goals of developing dynamic interventions and may hinder our ability to explore broader therapeutic avenues.
Resolution structure after processing: {
  "initiator": "Исследователи в области нейрологии",
  "resolution_description": "Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек",
  "new_actor": "Отредактированные изображения белковых бляшек",
  "participants": [],
  "required_participants": [
    {
      "participant": "Коллеги-ученые",
      "reasoning": "Коллеги-ученые are crucial for validating the amyloid hypothesis through collaboration on research methodologies and sharing expertise in neurobiology."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании are essential for the development and commercialization of potential treatments based on the findings from the manipulation of protein plaques."
    },
    {
      "participant": "Больница",
      "reasoning": "Больница is important for providing clinical context, patient access, and facilitating trials necessary to test the implications of the research on Alzheimer's disease."
    }
  ]
}
Resolution by Исследователи в области нейрологии has collapsed due to lack of participants.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', '3D iPSC-based organoids']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is the initiator of the resolution: 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследование механизмов патогенеза болезни Альцгеймера и разработка новых методов диагностики.' by performing 'Проведение клинических испытаний и анализ данных от пациентов с деменцией.'. However, under the proposed resolution 'As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.', you as 'Исследователи в области нейрологии' will be able to achieve 'Ускорить разработку эффективных терапий для лечения болезни Альцгеймера.' by performing 'Сосредоточиться на разработке и тестировании новых лекарственных средств, направленных на замедление прогрессирования болезни.' using 'Создание междисциплинарной исследовательской группы для совместной работы над инновационными подходами к лечению и использованию новых технологий в исследованиях.' that 'Alzheimer's Disease' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии declined the resolution proposed by Alzheimer's Disease with reasoning: The proposed resolution shifts focus away from confirming the amyloid hypothesis, which is my primary desire and goal. While the new approach might offer innovative treatment methods, it risks undermining years of research invested in the amyloid hypothesis and could jeopardize my reputation and funding if perceived as abandoning established theories. Pursuing this proposal could lead to a loss of recognition in the scientific community and potential funding, which are critical to my ongoing research.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop effective pharmacological treatments for Alzheimer's Disease' by performing 'Conducting clinical trials for new drug candidates'. However, under the proposed resolution 'As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.', you as 'Фармакологические компании' will be able to achieve 'Accelerate the research and development of Alzheimer's Disease therapies' by performing 'Increase funding and resources allocated to Alzheimer's research projects' using 'Establish a collaborative network among pharmaceutical companies, research institutions, and healthcare providers to share data and best practices' that 'Alzheimer's Disease' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.",
  "new_actor": "Neuroplasticity-Regenerator Actor",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop effective pharmacological treatments for Alzheimer's Disease",
        "current_action": "Conducting clinical trials for new drug candidates",
        "imposed_goal": "Accelerate the research and development of Alzheimer's Disease therapies",
        "imposed_action": "Increase funding and resources allocated to Alzheimer's research projects",
        "mechanism": "Establish a collaborative network among pharmaceutical companies, research institutions, and healthcare providers to share data and best practices",
        "reasoning": "The proposed resolution offers a novel approach to understanding and treating Alzheimer's Disease by leveraging the body's immune response and neuroplasticity. This aligns with the desire to develop effective treatments and potentially leads to groundbreaking discoveries that could be patented. Additionally, increasing funding and establishing a collaborative network can mitigate the risks associated with investment losses by pooling resources, sharing data, and reducing competition, thus enhancing the likelihood of successful outcomes in research and development."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments. They have the resources and infrastructure needed to develop and commercialize therapies that leverage the body's immune response and neuroplasticity."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are significant for modeling Alzheimer's disease and testing potential therapies in vitro. They can help in understanding how to repair and regenerate neural pathways affected by the disease."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids provide a sophisticated platform for studying disease mechanisms and testing new treatments in a more physiologically relevant context. Their use is critical for evaluating the effectiveness of the proposed neuroplasticity strategies."
    }
  ]
}
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is the initiator of the resolution: 'As 'iPSCs', propose a resolution to tackle Alzheimer's disease by creating a dynamic, patient-specific "neural time machine" that uses iPSC-derived neural cells to not only model disease progression in real-time but also reverse-engineer the cellular aging process, offering unprecedented insights into early intervention strategies and cellular rejuvenation therapies that challenge and expand beyond the boundaries of conventional hypotheses.'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To advance research and therapeutic applications using iPSCs in various diseases.' by performing 'Generating and differentiating iPSCs for experimental studies.'. However, under the proposed resolution 'As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To develop effective treatments for Alzheimer's Disease using iPSCs.' by performing 'Focus on creating specific neuronal cell types from iPSCs to study Alzheimer's pathology and potential therapies.' using 'Establish collaborations with Alzheimer’s research centers to align iPSC-derived research with ongoing clinical trials and therapeutic studies.' that 'Alzheimer's Disease' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.",
  "new_actor": "Neuroplasticity-Regenerator Actor",
  "participants": [
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance research and therapeutic applications using iPSCs in various diseases.",
        "current_action": "Generating and differentiating iPSCs for experimental studies.",
        "imposed_goal": "To develop effective treatments for Alzheimer's Disease using iPSCs.",
        "imposed_action": "Focus on creating specific neuronal cell types from iPSCs to study Alzheimer's pathology and potential therapies.",
        "mechanism": "Establish collaborations with Alzheimer’s research centers to align iPSC-derived research with ongoing clinical trials and therapeutic studies.",
        "reasoning": "The proposed approach to leverage the body's immune response and neuroplasticity aligns with the overarching goal of advancing treatments for Alzheimer's Disease. By utilizing iPSCs to create specific neuronal cell types and establishing collaborations with research centers, this proposal offers a promising avenue for innovative therapies. It enhances the understanding of disease mechanisms while potentially leading to effective interventions, which aligns with the interests of iPSCs in contributing to significant advancements in Alzheimer’s research."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments. They have the resources and infrastructure needed to develop and commercialize therapies that leverage the body's immune response and neuroplasticity."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are significant for modeling Alzheimer's disease and testing potential therapies in vitro. They can help in understanding how to repair and regenerate neural pathways affected by the disease."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids provide a sophisticated platform for studying disease mechanisms and testing new treatments in a more physiologically relevant context. Their use is critical for evaluating the effectiveness of the proposed neuroplasticity strategies."
    }
  ]
}
Resolution by induced pluripotent stem cells (iPSCs) has collapsed due to departure of induced pluripotent stem cells (iPSCs)
Resolution by induced pluripotent stem cells (iPSCs) has collapsed.
We ask '3D iPSC-based organoids' the following: 'As the representative of a being called '3D iPSC-based organoids', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, '3D iPSC-based organoids' is the initiator of the resolution: 'As '3D iPSC-based organoids,' propose a resolution to tackle Alzheimer's disease by engineering complex, multi-cellular brain organoids that replicate the intricate human brain microenvironment, enabling the discovery and testing of novel therapeutic compounds that target the synergistic interactions of diverse cell types and pathways involved in Alzheimer's pathology, thus offering a transformative approach that redefines our understanding and treatment of the disease beyond existing models and hypotheses.'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, '3D iPSC-based organoids', the entity you represent, that now you achieve 'Develop advanced models for studying neural diseases' by performing 'Creating 3D iPSC-based organoids that mimic brain tissue'. However, under the proposed resolution 'As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.', you as '3D iPSC-based organoids' will be able to achieve 'Accelerate research on Alzheimer's Disease mechanisms and treatments' by performing 'Focus on generating organoids specifically designed to replicate Alzheimer's pathology' using 'Implementing collaborative research initiatives with Alzheimer's researchers to align organoid models with disease-specific studies' that 'Alzheimer's Disease' will control. Based on '3D iPSC-based organoids' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as '3D iPSC-based organoids'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
3D iPSC-based organoids agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.",
  "new_actor": "Neuroplasticity-Regenerator Actor",
  "participants": [
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "Develop advanced models for studying neural diseases",
        "current_action": "Creating 3D iPSC-based organoids that mimic brain tissue",
        "imposed_goal": "Accelerate research on Alzheimer's Disease mechanisms and treatments",
        "imposed_action": "Focus on generating organoids specifically designed to replicate Alzheimer's pathology",
        "mechanism": "Implementing collaborative research initiatives with Alzheimer's researchers to align organoid models with disease-specific studies",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns well with the capabilities of '3D iPSC-based organoids' and offers a significant opportunity to enhance research on Alzheimer's mechanisms and treatments. By leveraging the body's immune response and focusing on neuroplasticity, we can create organoids that not only mimic Alzheimer's pathology but also allow for the exploration of innovative therapeutic strategies. This collaborative effort will facilitate the development of advanced models that could lead to breakthroughs in understanding and treating the disease, thus benefiting our overall research goals."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments. They have the resources and infrastructure needed to develop and commercialize therapies that leverage the body's immune response and neuroplasticity."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are significant for modeling Alzheimer's disease and testing potential therapies in vitro. They can help in understanding how to repair and regenerate neural pathways affected by the disease."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids provide a sophisticated platform for studying disease mechanisms and testing new treatments in a more physiologically relevant context. Their use is critical for evaluating the effectiveness of the proposed neuroplasticity strategies."
    }
  ]
}
Resolution by 3D iPSC-based organoids has collapsed due to departure of 3D iPSC-based organoids
Resolution by 3D iPSC-based organoids has collapsed.
Resolution structure after processing: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As Alzheimer's Disease, leverage the body's own immune response by developing a method to safely trigger and harness the brain's innate neuroplasticity to repair and regenerate neural pathways affected by the disease, thus offering a groundbreaking approach to understanding and treating Alzheimer's beyond the conventional amyloid hypothesis.",
  "new_actor": "Neuroplasticity-Regenerator Actor",
  "participants": [],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments. They have the resources and infrastructure needed to develop and commercialize therapies that leverage the body's immune response and neuroplasticity."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are significant for modeling Alzheimer's disease and testing potential therapies in vitro. They can help in understanding how to repair and regenerate neural pathways affected by the disease."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids provide a sophisticated platform for studying disease mechanisms and testing new treatments in a more physiologically relevant context. Their use is critical for evaluating the effectiveness of the proposed neuroplasticity strategies."
    }
  ]
}
Resolution by Alzheimer's Disease has collapsed due to lack of participants.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', '3D iPSC-based organoids']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is the initiator of the resolution: 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'Tau protein' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследовать механизмы патологии тау-белка в нейродегенеративных заболеваниях' by performing 'Проведение экспериментов на клеточных культурах и животных моделях'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.', you as 'Исследователи в области нейрологии' will be able to achieve 'Разработать терапевтические стратегии для ингибирования тау-белка' by performing 'Сфокусироваться на поиске потенциальных ингибиторов тау-белка через высокопроизводительный скрининг' using 'Создание сотрудничества с фармацевтическими компаниями для совместной работы над новыми веществами' that 'Tau protein' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии declined the resolution proposed by Tau protein with reasoning: The proposed resolution challenges the established amyloid hypothesis, which is the focus of my current research and recognition goals. Accepting this proposal may undermine my efforts to confirm the amyloid hypothesis and could lead to loss of funding and reputation if the new approach does not yield positive results. While exploring tau protein's role is important, it diverts from my immediate objectives and increases the risk of failure in both research and funding.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Tau protein' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop new pharmacological treatments for neurodegenerative diseases' by performing 'Conducting research and clinical trials on existing compounds'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.', you as 'Фармакологические компании' will be able to achieve 'Focus on developing Tau protein-targeting therapies' by performing 'Allocate resources toward research specifically aimed at Tau protein modulation' using 'Establish collaborative partnerships with research institutions to share data and findings related to Tau protein and its implications in neurodegeneration' that 'Tau protein' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.",
  "new_actor": "Tau Dynamics Stabilizer (TDS) Actor",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological treatments for neurodegenerative diseases",
        "current_action": "Conducting research and clinical trials on existing compounds",
        "imposed_goal": "Focus on developing Tau protein-targeting therapies",
        "imposed_action": "Allocate resources toward research specifically aimed at Tau protein modulation",
        "mechanism": "Establish collaborative partnerships with research institutions to share data and findings related to Tau protein and its implications in neurodegeneration",
        "reasoning": "The proposed resolution aligns with the desire to develop and patent an effective Alzheimer's treatment by focusing on Tau protein, which is a promising therapeutic target. By allocating resources and establishing partnerships for research on Tau protein modulation, we can mitigate the risk of losing investments due to potential failures in traditional approaches centered around the amyloid hypothesis. This strategy diversifies our portfolio and enhances our competitive edge in the market, addressing both our desires for innovation and our fears of competition and investment loss."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners in the development and commercialization of new therapeutic pathways targeting tau protein. Their resources and research capabilities can facilitate the translation of findings into viable treatments for Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are valuable for modeling neuronal degeneration and testing potential therapies. Utilizing iPSCs can provide insights into tau dynamics in a controlled environment, helping to validate hypotheses and therapeutic approaches."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain's microenvironment, allowing for more accurate studies of tau protein interactions and therapeutic efficacy. They are essential in bridging the gap between laboratory findings and clinical applications."
    }
  ]
}
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Tau protein' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To maintain pluripotency and self-renewal capabilities.' by performing 'Undergoing regular cell division and differentiation into various cell types.'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To differentiate into a specific neuronal lineage to study Tau protein interactions.' by performing 'Initiate a directed differentiation protocol towards neuronal cells.' using 'Utilizing growth factors and small molecules to guide the differentiation process while monitoring Tau protein expression.' that 'Tau protein' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.",
  "new_actor": "Tau Dynamics Stabilizer (TDS) Actor",
  "participants": [
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To maintain pluripotency and self-renewal capabilities.",
        "current_action": "Undergoing regular cell division and differentiation into various cell types.",
        "imposed_goal": "To differentiate into a specific neuronal lineage to study Tau protein interactions.",
        "imposed_action": "Initiate a directed differentiation protocol towards neuronal cells.",
        "mechanism": "Utilizing growth factors and small molecules to guide the differentiation process while monitoring Tau protein expression.",
        "reasoning": "The proposal by 'Tau protein' presents a valuable opportunity for 'induced pluripotent stem cells (iPSCs)' to actively participate in an innovative approach to Alzheimer's disease research. By differentiating into neuronal lineages and studying Tau protein interactions, iPSCs can contribute to understanding the functional role of Tau in microtubule dynamics. This aligns with the interest in advancing stem cell research and therapeutic applications, ultimately promoting the potential for new treatments against neurodegenerative diseases."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners in the development and commercialization of new therapeutic pathways targeting tau protein. Their resources and research capabilities can facilitate the translation of findings into viable treatments for Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are valuable for modeling neuronal degeneration and testing potential therapies. Utilizing iPSCs can provide insights into tau dynamics in a controlled environment, helping to validate hypotheses and therapeutic approaches."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain's microenvironment, allowing for more accurate studies of tau protein interactions and therapeutic efficacy. They are essential in bridging the gap between laboratory findings and clinical applications."
    }
  ]
}
We ask '3D iPSC-based organoids' the following: 'As the representative of a being called '3D iPSC-based organoids', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Tau protein' wants to challenge existing status quo and says to you, '3D iPSC-based organoids', the entity you represent, that now you achieve 'Develop functional brain organoids for disease modeling and drug testing.' by performing 'Culturing and differentiating induced pluripotent stem cells (iPSCs) into brain organoids.'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.', you as '3D iPSC-based organoids' will be able to achieve 'Investigate the role of Tau protein in neurodegenerative diseases using 3D iPSC-based organoids.' by performing 'Conduct experiments to manipulate Tau protein levels and observe effects on organoid development and function.' using 'Utilize CRISPR/Cas9 gene editing to create Tau protein knock-out and overexpression models within the brain organoids.' that 'Tau protein' will control. Based on '3D iPSC-based organoids' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as '3D iPSC-based organoids'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
3D iPSC-based organoids agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.",
  "new_actor": "Tau Dynamics Stabilizer (TDS) Actor",
  "participants": [
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "Develop functional brain organoids for disease modeling and drug testing.",
        "current_action": "Culturing and differentiating induced pluripotent stem cells (iPSCs) into brain organoids.",
        "imposed_goal": "Investigate the role of Tau protein in neurodegenerative diseases using 3D iPSC-based organoids.",
        "imposed_action": "Conduct experiments to manipulate Tau protein levels and observe effects on organoid development and function.",
        "mechanism": "Utilize CRISPR/Cas9 gene editing to create Tau protein knock-out and overexpression models within the brain organoids.",
        "reasoning": "The proposed resolution aligns well with the capabilities of 3D iPSC-based organoids to model neurodegenerative diseases, particularly Alzheimer's. By investigating the role of Tau protein using organoids, we can gain insights into its functional dynamics and develop therapeutic strategies. This initiative not only enhances our understanding of Tau's role in neuronal health but also contributes to the advancement of drug testing and disease modeling, which is beneficial for the overall research goals of 3D iPSC-based organoids."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners in the development and commercialization of new therapeutic pathways targeting tau protein. Their resources and research capabilities can facilitate the translation of findings into viable treatments for Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are valuable for modeling neuronal degeneration and testing potential therapies. Utilizing iPSCs can provide insights into tau dynamics in a controlled environment, helping to validate hypotheses and therapeutic approaches."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain's microenvironment, allowing for more accurate studies of tau protein interactions and therapeutic efficacy. They are essential in bridging the gap between laboratory findings and clinical applications."
    }
  ]
}
Resolution structure after processing: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to combat Alzheimer's disease by developing advanced techniques to stabilize and enhance the functional role of tau in microtubule dynamics, thereby preventing neuronal degeneration and cognitive decline through a novel therapeutic pathway that complements or bypasses the amyloid hypothesis.",
  "new_actor": "Tau Dynamics Stabilizer (TDS) Actor",
  "participants": [],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners in the development and commercialization of new therapeutic pathways targeting tau protein. Their resources and research capabilities can facilitate the translation of findings into viable treatments for Alzheimer's disease."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are valuable for modeling neuronal degeneration and testing potential therapies. Utilizing iPSCs can provide insights into tau dynamics in a controlled environment, helping to validate hypotheses and therapeutic approaches."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain's microenvironment, allowing for more accurate studies of tau protein interactions and therapeutic efficacy. They are essential in bridging the gap between laboratory findings and clinical applications."
    }
  ]
}
Resolution by Tau protein has collapsed due to lack of participants.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', '3D iPSC-based organoids']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'APOE ɛ4' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is the initiator of the resolution: 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'APOE ɛ4' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследовать влияние генетики на развитие нейродегенеративных заболеваний' by performing 'Проведение клинических испытаний и анализ данных'. However, under the proposed resolution 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.', you as 'Исследователи в области нейрологии' will be able to achieve 'Установить связь между генотипом APOE ɛ4 и развитием болезни Альцгеймера' by performing 'Собрать и проанализировать данные о пациентах с генотипом APOE ɛ4' using 'Создание базы данных для совместного анализа и обмена информацией между исследователями' that 'APOE ɛ4' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии suggested modifying the proposal with reasoning: While the proposal by 'APOE ɛ4' presents an innovative approach to tackling Alzheimer's disease through a personalized genomic strategy, it diverges significantly from the current focus on the amyloid hypothesis that 'Исследователи в области нейрологии' aims to confirm. To align the proposal with our desires to validate the amyloid hypothesis and maintain credibility in the scientific community, it would be beneficial to integrate aspects of the proposed genomic approach into our existing framework. This could involve investigating how genetic factors, including APOE ɛ4, influence amyloid pathology and contribute to the disease, thereby reinforcing our original resolution while expanding our research scope.
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'APOE ɛ4' with a resolution to deal with the current controversy. Currently, 'Исследователи в области нейрологии' is the initiator of the resolution: 'Подтверждение амилоидной гипотезы болезни Альцгеймера путем манипуляции изображениями белковых бляшек'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'APOE ɛ4' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Изучение генетических факторов, влияющих на болезни мозга.' by performing 'Проведение клинических испытаний и анализ данных.'. However, under the proposed resolution 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.', you as 'Исследователи в области нейрологии' will be able to achieve 'Углубленное исследование влияния APOE ε4 на развитие альцгеймера.' by performing 'Разработка и реализация новых исследований, направленных на изучение механизмов действия APOE ε4.' using 'Создание междисциплинарной исследовательской группы для совместной работы над проектами, связанными с APOE ε4.' that 'APOE ɛ4' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES or NO. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES or NO
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Resolution by Исследователи в области нейрологии has collapsed due to departure of initiator.
Исследователи в области нейрологии agreed to participate in the resolution proposed by APOE ɛ4
Resolution by Исследователи в области нейрологии has collapsed.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'APOE ɛ4' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'APOE ɛ4' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop and market new pharmacological treatments for Alzheimer's disease.' by performing 'Conducting clinical trials and research on drug efficacy.'. However, under the proposed resolution 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.', you as 'Фармакологические компании' will be able to achieve 'Focus on developing treatments specifically targeting APOE ɛ4 carriers.' by performing 'Allocate resources to research and development of tailored therapies for the APOE ɛ4 population.' using 'Establish partnerships with research institutions to share data and insights on APOE ɛ4 and its implications in Alzheimer's.' that 'APOE ɛ4' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by APOE ɛ4
Updated resolution structure: {
  "initiator": "APOE ɛ4",
  "resolution_description": "As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.",
  "new_actor": "NeuroGenomics Initiative for Alzheimer's Therapy",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение генетических факторов, влияющих на болезни мозга.",
        "current_action": "Проведение клинических испытаний и анализ данных.",
        "imposed_goal": "Углубленное исследование влияния APOE ε4 на развитие альцгеймера.",
        "imposed_action": "Разработка и реализация новых исследований, направленных на изучение механизмов действия APOE ε4.",
        "mechanism": "Создание междисциплинарной исследовательской группы для совместной работы над проектами, связанными с APOE ε4.",
        "reasoning": "The proposed resolution by 'APOE ɛ4' aligns well with my desires to deepen the understanding of Alzheimer's disease through a focus on genetic factors, particularly the role of APOE ε4. It offers a transformative strategy that could redefine risk assessment and therapeutic interventions, potentially leading to significant advancements in the field. Additionally, collaborating on this innovative approach may mitigate my fears regarding the validation of the amyloid hypothesis by providing a broader research framework, reducing the risk of reputational damage associated with data manipulation, and opening up new funding opportunities."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop and market new pharmacological treatments for Alzheimer's disease.",
        "current_action": "Conducting clinical trials and research on drug efficacy.",
        "imposed_goal": "Focus on developing treatments specifically targeting APOE ɛ4 carriers.",
        "imposed_action": "Allocate resources to research and development of tailored therapies for the APOE ɛ4 population.",
        "mechanism": "Establish partnerships with research institutions to share data and insights on APOE ɛ4 and its implications in Alzheimer's.",
        "reasoning": "The proposed resolution aligns with our desire to develop and patent effective treatments for Alzheimer's disease, particularly by focusing on a specific population (APOE ɛ4 carriers). This personalized genomic approach to modify lipid metabolism pathways presents an innovative strategy that could lead to a breakthrough in treatment options. By allocating resources for tailored therapies and establishing partnerships for research, we can enhance our competitive edge in the market, potentially mitigating the risk of losing investments due to unsuccessful drug development."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for advancing the understanding of Alzheimer's disease and developing the personalized genomic approaches necessary for modifying lipid metabolism pathways in the brain."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources, expertise, and infrastructure to develop and bring new therapeutic interventions to market based on the proposed genomic strategies."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in modeling Alzheimer's disease and testing the effectiveness of new treatments aimed at enhancing neuronal resilience and synaptic repair mechanisms."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids will facilitate more accurate in vitro studies of Alzheimer's disease, enabling the testing of personalized genomic strategies in a controlled environment that mimics human brain tissue."
    }
  ]
}
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'APOE ɛ4' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'APOE ɛ4' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To develop therapies for neurodegenerative diseases using induced pluripotent stem cells.' by performing 'Differentiating iPSCs into specific neuronal cell types for research.'. However, under the proposed resolution 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To accelerate the understanding of Alzheimer’s disease mechanisms linked to APOE ɛ4.' by performing 'Utilizing iPSCs to create in vitro models that mimic APOE ɛ4-associated neurodegeneration.' using 'Establishing a collaborative framework for sharing iPSC-derived data and findings that focus on APOE ɛ4-related pathways.' that 'APOE ɛ4' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by APOE ɛ4
Updated resolution structure: {
  "initiator": "APOE ɛ4",
  "resolution_description": "As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.",
  "new_actor": "NeuroGenomics Initiative for Alzheimer's Therapy",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение генетических факторов, влияющих на болезни мозга.",
        "current_action": "Проведение клинических испытаний и анализ данных.",
        "imposed_goal": "Углубленное исследование влияния APOE ε4 на развитие альцгеймера.",
        "imposed_action": "Разработка и реализация новых исследований, направленных на изучение механизмов действия APOE ε4.",
        "mechanism": "Создание междисциплинарной исследовательской группы для совместной работы над проектами, связанными с APOE ε4.",
        "reasoning": "The proposed resolution by 'APOE ɛ4' aligns well with my desires to deepen the understanding of Alzheimer's disease through a focus on genetic factors, particularly the role of APOE ε4. It offers a transformative strategy that could redefine risk assessment and therapeutic interventions, potentially leading to significant advancements in the field. Additionally, collaborating on this innovative approach may mitigate my fears regarding the validation of the amyloid hypothesis by providing a broader research framework, reducing the risk of reputational damage associated with data manipulation, and opening up new funding opportunities."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To develop therapies for neurodegenerative diseases using induced pluripotent stem cells.",
        "current_action": "Differentiating iPSCs into specific neuronal cell types for research.",
        "imposed_goal": "To accelerate the understanding of Alzheimer’s disease mechanisms linked to APOE ɛ4.",
        "imposed_action": "Utilizing iPSCs to create in vitro models that mimic APOE ɛ4-associated neurodegeneration.",
        "mechanism": "Establishing a collaborative framework for sharing iPSC-derived data and findings that focus on APOE ɛ4-related pathways.",
        "reasoning": "The proposed resolution aligns perfectly with the goals of induced pluripotent stem cells (iPSCs) to deepen the understanding of Alzheimer's disease mechanisms associated with APOE ɛ4. By utilizing iPSCs to create in vitro models, we can explore the specific pathways related to lipid metabolism and neuronal resilience, facilitating innovative therapeutic strategies. This collaboration not only enhances the relevance of iPSC research but also contributes to meaningful advancements in neurodegenerative disease treatment."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for advancing the understanding of Alzheimer's disease and developing the personalized genomic approaches necessary for modifying lipid metabolism pathways in the brain."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources, expertise, and infrastructure to develop and bring new therapeutic interventions to market based on the proposed genomic strategies."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in modeling Alzheimer's disease and testing the effectiveness of new treatments aimed at enhancing neuronal resilience and synaptic repair mechanisms."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids will facilitate more accurate in vitro studies of Alzheimer's disease, enabling the testing of personalized genomic strategies in a controlled environment that mimics human brain tissue."
    }
  ]
}
We ask '3D iPSC-based organoids' the following: 'As the representative of a being called '3D iPSC-based organoids', you have been approached by 'APOE ɛ4' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'APOE ɛ4' wants to challenge existing status quo and says to you, '3D iPSC-based organoids', the entity you represent, that now you achieve 'Develop 3D iPSC-based organoids for disease modeling and drug testing.' by performing 'Culturing induced pluripotent stem cells (iPSCs) and differentiating them into organoids.'. However, under the proposed resolution 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.', you as '3D iPSC-based organoids' will be able to achieve 'Enhance the understanding of APOE ɛ4's role in neurodegenerative diseases using organoids.' by performing 'Incorporate APOE ɛ4 variants into the organoid models for comparative analysis.' using 'Utilize CRISPR technology to engineer iPSCs with APOE ɛ4 alleles, allowing for targeted studies of its effects on organoid development and function.' that 'APOE ɛ4' will control. Based on '3D iPSC-based organoids' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as '3D iPSC-based organoids'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
3D iPSC-based organoids agreed to participate in the resolution proposed by APOE ɛ4
Updated resolution structure: {
  "initiator": "APOE ɛ4",
  "resolution_description": "As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.",
  "new_actor": "NeuroGenomics Initiative for Alzheimer's Therapy",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение генетических факторов, влияющих на болезни мозга.",
        "current_action": "Проведение клинических испытаний и анализ данных.",
        "imposed_goal": "Углубленное исследование влияния APOE ε4 на развитие альцгеймера.",
        "imposed_action": "Разработка и реализация новых исследований, направленных на изучение механизмов действия APOE ε4.",
        "mechanism": "Создание междисциплинарной исследовательской группы для совместной работы над проектами, связанными с APOE ε4.",
        "reasoning": "The proposed resolution by 'APOE ɛ4' aligns well with my desires to deepen the understanding of Alzheimer's disease through a focus on genetic factors, particularly the role of APOE ε4. It offers a transformative strategy that could redefine risk assessment and therapeutic interventions, potentially leading to significant advancements in the field. Additionally, collaborating on this innovative approach may mitigate my fears regarding the validation of the amyloid hypothesis by providing a broader research framework, reducing the risk of reputational damage associated with data manipulation, and opening up new funding opportunities."
      }
    },
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "Develop 3D iPSC-based organoids for disease modeling and drug testing.",
        "current_action": "Culturing induced pluripotent stem cells (iPSCs) and differentiating them into organoids.",
        "imposed_goal": "Enhance the understanding of APOE ɛ4's role in neurodegenerative diseases using organoids.",
        "imposed_action": "Incorporate APOE ɛ4 variants into the organoid models for comparative analysis.",
        "mechanism": "Utilize CRISPR technology to engineer iPSCs with APOE ɛ4 alleles, allowing for targeted studies of its effects on organoid development and function.",
        "reasoning": "The proposal presents a significant opportunity for '3D iPSC-based organoids' to enhance understanding of neurodegenerative diseases, specifically Alzheimer's disease, through the incorporation of APOE ɛ4 variants. This aligns with the goal of developing organoids for disease modeling and drug testing, and utilizing CRISPR technology allows for precise manipulation of genetic factors. This approach not only expands the capabilities of organoid models but also positions them at the forefront of personalized genomic research, potentially leading to transformative insights and therapeutic strategies."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for advancing the understanding of Alzheimer's disease and developing the personalized genomic approaches necessary for modifying lipid metabolism pathways in the brain."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources, expertise, and infrastructure to develop and bring new therapeutic interventions to market based on the proposed genomic strategies."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in modeling Alzheimer's disease and testing the effectiveness of new treatments aimed at enhancing neuronal resilience and synaptic repair mechanisms."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids will facilitate more accurate in vitro studies of Alzheimer's disease, enabling the testing of personalized genomic strategies in a controlled environment that mimics human brain tissue."
    }
  ]
}
Resolution structure after processing: {
  "initiator": "APOE ɛ4",
  "resolution_description": "As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.",
  "new_actor": "NeuroGenomics Initiative for Alzheimer's Therapy",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение генетических факторов, влияющих на болезни мозга.",
        "current_action": "Проведение клинических испытаний и анализ данных.",
        "imposed_goal": "Углубленное исследование влияния APOE ε4 на развитие альцгеймера.",
        "imposed_action": "Разработка и реализация новых исследований, направленных на изучение механизмов действия APOE ε4.",
        "mechanism": "Создание междисциплинарной исследовательской группы для совместной работы над проектами, связанными с APOE ε4.",
        "reasoning": "The proposed resolution by 'APOE ɛ4' aligns well with my desires to deepen the understanding of Alzheimer's disease through a focus on genetic factors, particularly the role of APOE ε4. It offers a transformative strategy that could redefine risk assessment and therapeutic interventions, potentially leading to significant advancements in the field. Additionally, collaborating on this innovative approach may mitigate my fears regarding the validation of the amyloid hypothesis by providing a broader research framework, reducing the risk of reputational damage associated with data manipulation, and opening up new funding opportunities."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for advancing the understanding of Alzheimer's disease and developing the personalized genomic approaches necessary for modifying lipid metabolism pathways in the brain."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources, expertise, and infrastructure to develop and bring new therapeutic interventions to market based on the proposed genomic strategies."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in modeling Alzheimer's disease and testing the effectiveness of new treatments aimed at enhancing neuronal resilience and synaptic repair mechanisms."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids will facilitate more accurate in vitro studies of Alzheimer's disease, enabling the testing of personalized genomic strategies in a controlled environment that mimics human brain tissue."
    }
  ]
}
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'Пациенты', 'Blood-brain barrier (BBB)']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'PBM treatment' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'APOE ɛ4' with the description: 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'PBM treatment' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследование эффектов PBM-терапии на нейродегенеративные заболевания' by performing 'Проведение клинических испытаний с участниками'. However, under the proposed resolution 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.', you as 'Исследователи в области нейрологии' will be able to achieve 'Оптимизация применения PBM-терапии для улучшения когнитивных функций' by performing 'Разработка протоколов для масштабируемых исследований' using 'Создание междисциплинарной группы для обмена данными и ресурсами' that 'PBM treatment' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии declined the resolution proposed by PBM treatment with reasoning: While the proposal from 'PBM treatment' offers an innovative approach to tackling Alzheimer's disease through photobiomodulation, it diverges significantly from my current focus on the amyloid hypothesis. My primary desire is to confirm the amyloid hypothesis and gain recognition within the scientific community based on that research. Joining 'PBM treatment' may jeopardize my ongoing studies and funding related to amyloid pathology, leading to a potential loss of years of research. Additionally, there is a risk that engaging in a divergent approach may impact my reputation if the amyloid hypothesis is ultimately validated.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'PBM treatment' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'PBM treatment' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop and market new pharmacological treatments' by performing 'Conducting clinical trials and research studies'. However, under the proposed resolution 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.', you as 'Фармакологические компании' will be able to achieve 'Increase accessibility of PBM treatments to patients' by performing 'Collaborate with PBM providers to ensure wider distribution' using 'Establish partnerships with PBM companies to streamline approval and reimbursement processes' that 'PBM treatment' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании suggested modifying the proposal with reasoning: While the proposal to utilize photobiomodulation (PBM) as a treatment for Alzheimer's disease is intriguing and presents a novel approach, it does not align directly with the current desire to develop and patent a pharmacological drug. Additionally, there are concerns regarding the lack of established clinical evidence for PBM's efficacy compared to traditional drug development pathways. To make the proposal more appealing, it should incorporate elements that allow for collaboration on drug development alongside PBM treatments, ensuring that the interests of Фармакологические компании in securing effective treatments and patents are maintained.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'PBM treatment' with a resolution to deal with the current controversy. 'PBM treatment' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'To develop and market new pharmaceutical products effectively.' by performing 'Conducting clinical trials and gathering regulatory approvals.'. However, under the proposed resolution 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.', you as 'Фармакологические компании' will be able to achieve 'To enhance patient access to medications through PBM treatment models.' by performing 'Collaborate with PBMs to create more affordable drug pricing strategies.' using 'Establishing agreements with PBMs to ensure that medications are included in their formularies, and implementing adherence programs to improve patient outcomes.' that 'PBM treatment' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES or NO. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES or NO
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by PBM treatment
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'PBM treatment' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'PBM treatment' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Manage chronic pain effectively' by performing 'Following prescribed medication regimen'. However, under the proposed resolution 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.', you as 'Пациенты' will be able to achieve 'Reduce pain levels by 50% within 3 months' by performing 'Engage in a structured physical therapy program' using 'Weekly check-ins with a healthcare provider to monitor progress and adjust treatment as necessary' that 'PBM treatment' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by PBM treatment
Updated resolution structure: {
  "initiator": "PBM treatment",
  "resolution_description": "As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.",
  "new_actor": "The actor created would be named \"Photobiomodulation Alzheimer's Therapy Initiative (PATI).\"",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "To develop and market new pharmaceutical products effectively.",
        "current_action": "Conducting clinical trials and gathering regulatory approvals.",
        "imposed_goal": "To enhance patient access to medications through PBM treatment models.",
        "imposed_action": "Collaborate with PBMs to create more affordable drug pricing strategies.",
        "mechanism": "Establishing agreements with PBMs to ensure that medications are included in their formularies, and implementing adherence programs to improve patient outcomes.",
        "reasoning": "The proposal from PBM treatment presents an innovative approach to tackling Alzheimer's disease through photobiomodulation, which aligns with my desire to develop an effective treatment. This method diverges from traditional treatments and could lead to a unique pharmaceutical product, potentially allowing for patenting and market exclusivity. Additionally, collaborating with PBMs to create affordable treatment models enhances patient access, which can improve market adoption and reduce the risk of losing investments due to competition. Overall, this proposal addresses my desire to innovate while providing a pathway to mitigate my fears of financial loss."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Manage chronic pain effectively",
        "current_action": "Following prescribed medication regimen",
        "imposed_goal": "Reduce pain levels by 50% within 3 months",
        "imposed_action": "Engage in a structured physical therapy program",
        "mechanism": "Weekly check-ins with a healthcare provider to monitor progress and adjust treatment as necessary",
        "reasoning": "The proposed resolution by 'PBM treatment' aligns well with my desire to live a full life without the symptoms of Alzheimer's disease. By focusing on non-invasive photobiomodulation to enhance mitochondrial function and stimulate neuroprotective pathways, this approach offers a promising alternative to traditional treatments that may not effectively address the progression of the disease. Additionally, the potential to halt or reverse neural damage directly addresses my fears of losing memory, identity, and independence. This innovative strategy not only aims to improve my current health but also provides hope for a better quality of life."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources and infrastructure to develop photobiomodulation therapies into viable products. Their involvement is crucial for scaling the treatment and ensuring regulatory compliance."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of any treatment. Engaging with them will help to understand their needs and experiences, which can inform treatment development and ensure that approaches are patient-centered."
    },
    {
      "participant": "Blood-brain barrier (BBB)",
      "reasoning": "The blood-brain barrier (BBB) is a critical factor in the delivery of therapies to the brain. Understanding how photobiomodulation interacts with the BBB will be vital for ensuring that the treatment is effective and reaches its target."
    }
  ]
}
We ask 'Blood-brain barrier (BBB)' the following: 'As the representative of a being called 'Blood-brain barrier (BBB)', you have been approached by 'PBM treatment' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Blood-brain barrier (BBB)' is the initiator of the resolution: 'As the 'Blood-brain barrier (BBB)', propose a revolutionary resolution to tackle Alzheimer's disease by developing a cutting-edge nanotechnology-based delivery system that selectively transports therapeutic agents across the BBB, precisely targeting and modulating brain regions affected by the disease, thus enabling unprecedented precision in treatment and opening new avenues for intervention beyond traditional hypotheses and methodologies.'. Leaving it for any new proposal will lead to collapse of resolution you initiated. 'PBM treatment' wants to challenge existing status quo and says to you, 'Blood-brain barrier (BBB)', the entity you represent, that now you achieve 'Protect the brain from harmful substances while allowing essential nutrients to pass through.' by performing 'Regulating permeability of the endothelial cells in the brain vasculature.'. However, under the proposed resolution 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.', you as 'Blood-brain barrier (BBB)' will be able to achieve 'Enhance the delivery of PBM treatment to targeted brain regions.' by performing 'Increase permeability temporarily to facilitate the entry of PBM light into the brain tissue.' using 'Utilize transient opening techniques such as focused ultrasound or chemical agents to enhance BBB permeability specifically during PBM treatment.' that 'PBM treatment' will control. Based on 'Blood-brain barrier (BBB)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'Blood-brain barrier (BBB)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Blood-brain barrier (BBB) agreed to participate in the resolution proposed by PBM treatment
Updated resolution structure: {
  "initiator": "PBM treatment",
  "resolution_description": "As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.",
  "new_actor": "The actor created would be named \"Photobiomodulation Alzheimer's Therapy Initiative (PATI).\"",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "To develop and market new pharmaceutical products effectively.",
        "current_action": "Conducting clinical trials and gathering regulatory approvals.",
        "imposed_goal": "To enhance patient access to medications through PBM treatment models.",
        "imposed_action": "Collaborate with PBMs to create more affordable drug pricing strategies.",
        "mechanism": "Establishing agreements with PBMs to ensure that medications are included in their formularies, and implementing adherence programs to improve patient outcomes.",
        "reasoning": "The proposal from PBM treatment presents an innovative approach to tackling Alzheimer's disease through photobiomodulation, which aligns with my desire to develop an effective treatment. This method diverges from traditional treatments and could lead to a unique pharmaceutical product, potentially allowing for patenting and market exclusivity. Additionally, collaborating with PBMs to create affordable treatment models enhances patient access, which can improve market adoption and reduce the risk of losing investments due to competition. Overall, this proposal addresses my desire to innovate while providing a pathway to mitigate my fears of financial loss."
      }
    },
    {
      "participant": "Blood-brain barrier (BBB)",
      "agreement_structure": {
        "current_goal": "Protect the brain from harmful substances while allowing essential nutrients to pass through.",
        "current_action": "Regulating permeability of the endothelial cells in the brain vasculature.",
        "imposed_goal": "Enhance the delivery of PBM treatment to targeted brain regions.",
        "imposed_action": "Increase permeability temporarily to facilitate the entry of PBM light into the brain tissue.",
        "mechanism": "Utilize transient opening techniques such as focused ultrasound or chemical agents to enhance BBB permeability specifically during PBM treatment.",
        "reasoning": "The proposed resolution by 'PBM treatment' aligns with my interests as 'Blood-brain barrier (BBB)' by enhancing the delivery of therapeutic agents to targeted brain regions through increased permeability. This collaboration allows for the integration of nanotechnology with photobiomodulation, potentially leading to innovative and effective strategies to tackle Alzheimer's disease while also preserving the protective functions of the BBB."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources and infrastructure to develop photobiomodulation therapies into viable products. Their involvement is crucial for scaling the treatment and ensuring regulatory compliance."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of any treatment. Engaging with them will help to understand their needs and experiences, which can inform treatment development and ensure that approaches are patient-centered."
    },
    {
      "participant": "Blood-brain barrier (BBB)",
      "reasoning": "The blood-brain barrier (BBB) is a critical factor in the delivery of therapies to the brain. Understanding how photobiomodulation interacts with the BBB will be vital for ensuring that the treatment is effective and reaches its target."
    }
  ]
}
Resolution by Blood-brain barrier (BBB) has collapsed due to departure of Blood-brain barrier (BBB)
Resolution by Blood-brain barrier (BBB) has collapsed.
Resolution structure after processing: {
  "initiator": "PBM treatment",
  "resolution_description": "As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.",
  "new_actor": "The actor created would be named \"Photobiomodulation Alzheimer's Therapy Initiative (PATI).\"",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "To develop and market new pharmaceutical products effectively.",
        "current_action": "Conducting clinical trials and gathering regulatory approvals.",
        "imposed_goal": "To enhance patient access to medications through PBM treatment models.",
        "imposed_action": "Collaborate with PBMs to create more affordable drug pricing strategies.",
        "mechanism": "Establishing agreements with PBMs to ensure that medications are included in their formularies, and implementing adherence programs to improve patient outcomes.",
        "reasoning": "The proposal from PBM treatment presents an innovative approach to tackling Alzheimer's disease through photobiomodulation, which aligns with my desire to develop an effective treatment. This method diverges from traditional treatments and could lead to a unique pharmaceutical product, potentially allowing for patenting and market exclusivity. Additionally, collaborating with PBMs to create affordable treatment models enhances patient access, which can improve market adoption and reduce the risk of losing investments due to competition. Overall, this proposal addresses my desire to innovate while providing a pathway to mitigate my fears of financial loss."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies can provide the necessary resources and infrastructure to develop photobiomodulation therapies into viable products. Their involvement is crucial for scaling the treatment and ensuring regulatory compliance."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of any treatment. Engaging with them will help to understand their needs and experiences, which can inform treatment development and ensure that approaches are patient-centered."
    },
    {
      "participant": "Blood-brain barrier (BBB)",
      "reasoning": "The blood-brain barrier (BBB) is a critical factor in the delivery of therapies to the brain. Understanding how photobiomodulation interacts with the BBB will be vital for ensuring that the treatment is effective and reaches its target."
    }
  ]
}
Resolution created by Alzheimer's Disease: As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', '3D iPSC-based organoids']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'APOE ɛ4' with the description: 'As 'APOE ɛ4,' propose a resolution to tackle Alzheimer's disease by pioneering a personalized genomic approach to modify lipid metabolism pathways in the brain, aiming to enhance neuronal resilience and synaptic repair mechanisms, thus offering a transformative strategy that redefines risk assessment and therapeutic intervention beyond existing hypotheses.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.' by performing 'Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.'. However, under the proposed resolution 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.', you as 'Исследователи в области нейрологии' will be able to achieve 'To accelerate the development of effective treatments for Alzheimer's disease.' by performing 'Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.' using 'Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.' that 'Alzheimer's Disease' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.",
  "new_actor": "Immunomodulatory Microglia Reprogrammer",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.",
        "current_action": "Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.",
        "imposed_goal": "To accelerate the development of effective treatments for Alzheimer's disease.",
        "imposed_action": "Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.",
        "mechanism": "Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns with my desire to advance understanding of neurodegenerative processes and identify potential therapeutic targets. By collaborating with pharmaceutical companies and establishing a consortium, I can enhance the credibility of my research and potentially validate the amyloid hypothesis through innovative approaches. Additionally, this proposal mitigates my fears of losing funding and reputation, as it focuses on collaborative research and development of new drug candidates rather than solely relying on the amyloid hypothesis."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for developing and validating the proposed immunomodulation strategy. Their expertise will help in understanding the underlying mechanisms of Alzheimer's disease and in designing experiments to test the efficacy of reprogrammed microglial cells."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating the research findings into viable treatments. They have the resources and expertise to develop, manufacture, and commercialize therapies based on the proposed immunomodulation strategy."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in creating cellular models to study Alzheimer's pathology and the effectiveness of the new treatment strategy. They provide a platform for testing the reprogrammed microglial cells in a controlled environment."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain environment and are valuable for testing the interactions of reprogrammed microglial cells with aberrant protein aggregates. They will help in understanding the treatment's impact in a more physiologically relevant context."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'PBM treatment' with the description: 'As 'PBM treatment,' propose a resolution to tackle Alzheimer's disease by utilizing photobiomodulation to non-invasively enhance mitochondrial function and stimulate neuroprotective pathways in the brain, offering a revolutionary approach that leverages light-based therapy to potentially halt or reverse the progression of neural damage, thereby presenting a unique alternative that diverges from traditional hypotheses and treatments.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop innovative treatments for Alzheimer's Disease' by performing 'Conducting clinical trials for new drugs targeting symptoms and progression of Alzheimer's Disease'. However, under the proposed resolution 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.', you as 'Фармакологические компании' will be able to achieve 'Accelerate the discovery of disease-modifying therapies for Alzheimer's Disease' by performing 'Increase investment in research collaborations with academic institutions and research organizations focused on Alzheimer's Disease' using 'Establish a funding and resource-sharing platform that facilitates partnerships between pharmacological companies and research entities to foster innovative solutions and expedite drug development.' that 'Alzheimer's Disease' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.",
  "new_actor": "Immunomodulatory Microglia Reprogrammer",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.",
        "current_action": "Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.",
        "imposed_goal": "To accelerate the development of effective treatments for Alzheimer's disease.",
        "imposed_action": "Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.",
        "mechanism": "Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns with my desire to advance understanding of neurodegenerative processes and identify potential therapeutic targets. By collaborating with pharmaceutical companies and establishing a consortium, I can enhance the credibility of my research and potentially validate the amyloid hypothesis through innovative approaches. Additionally, this proposal mitigates my fears of losing funding and reputation, as it focuses on collaborative research and development of new drug candidates rather than solely relying on the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative treatments for Alzheimer's Disease",
        "current_action": "Conducting clinical trials for new drugs targeting symptoms and progression of Alzheimer's Disease",
        "imposed_goal": "Accelerate the discovery of disease-modifying therapies for Alzheimer's Disease",
        "imposed_action": "Increase investment in research collaborations with academic institutions and research organizations focused on Alzheimer's Disease",
        "mechanism": "Establish a funding and resource-sharing platform that facilitates partnerships between pharmacological companies and research entities to foster innovative solutions and expedite drug development.",
        "reasoning": "The proposed resolution to harness the body's immune system through adaptive immunomodulation aligns well with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's Disease. It offers an innovative approach that could lead to disease-modifying therapies, potentially reducing the risk of losing investments associated with traditional symptom management strategies. By increasing collaboration with academic institutions and establishing a funding platform, this proposal mitigates fears of failure and keeps 'Фармакологические компании' at the forefront of Alzheimer's research and treatment development."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for developing and validating the proposed immunomodulation strategy. Their expertise will help in understanding the underlying mechanisms of Alzheimer's disease and in designing experiments to test the efficacy of reprogrammed microglial cells."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating the research findings into viable treatments. They have the resources and expertise to develop, manufacture, and commercialize therapies based on the proposed immunomodulation strategy."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in creating cellular models to study Alzheimer's pathology and the effectiveness of the new treatment strategy. They provide a platform for testing the reprogrammed microglial cells in a controlled environment."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain environment and are valuable for testing the interactions of reprogrammed microglial cells with aberrant protein aggregates. They will help in understanding the treatment's impact in a more physiologically relevant context."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To advance the understanding of cellular mechanisms and potential treatments for Alzheimer's Disease.' by performing 'Conducting research on cellular models of Alzheimer's using iPSCs.'. However, under the proposed resolution 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To develop effective therapies for Alzheimer's Disease using iPSCs.' by performing 'Create and test iPSC-derived neurons to evaluate therapeutic interventions.' using 'Utilize high-throughput screening of drug candidates on iPSC-derived neurons to identify potential Alzheimer's treatments.' that 'Alzheimer's Disease' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.",
  "new_actor": "Immunomodulatory Microglia Reprogrammer",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.",
        "current_action": "Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.",
        "imposed_goal": "To accelerate the development of effective treatments for Alzheimer's disease.",
        "imposed_action": "Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.",
        "mechanism": "Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns with my desire to advance understanding of neurodegenerative processes and identify potential therapeutic targets. By collaborating with pharmaceutical companies and establishing a consortium, I can enhance the credibility of my research and potentially validate the amyloid hypothesis through innovative approaches. Additionally, this proposal mitigates my fears of losing funding and reputation, as it focuses on collaborative research and development of new drug candidates rather than solely relying on the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative treatments for Alzheimer's Disease",
        "current_action": "Conducting clinical trials for new drugs targeting symptoms and progression of Alzheimer's Disease",
        "imposed_goal": "Accelerate the discovery of disease-modifying therapies for Alzheimer's Disease",
        "imposed_action": "Increase investment in research collaborations with academic institutions and research organizations focused on Alzheimer's Disease",
        "mechanism": "Establish a funding and resource-sharing platform that facilitates partnerships between pharmacological companies and research entities to foster innovative solutions and expedite drug development.",
        "reasoning": "The proposed resolution to harness the body's immune system through adaptive immunomodulation aligns well with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's Disease. It offers an innovative approach that could lead to disease-modifying therapies, potentially reducing the risk of losing investments associated with traditional symptom management strategies. By increasing collaboration with academic institutions and establishing a funding platform, this proposal mitigates fears of failure and keeps 'Фармакологические компании' at the forefront of Alzheimer's research and treatment development."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance the understanding of cellular mechanisms and potential treatments for Alzheimer's Disease.",
        "current_action": "Conducting research on cellular models of Alzheimer's using iPSCs.",
        "imposed_goal": "To develop effective therapies for Alzheimer's Disease using iPSCs.",
        "imposed_action": "Create and test iPSC-derived neurons to evaluate therapeutic interventions.",
        "mechanism": "Utilize high-throughput screening of drug candidates on iPSC-derived neurons to identify potential Alzheimer's treatments.",
        "reasoning": "The proposed resolution aligns with the goals of induced pluripotent stem cells (iPSCs) to contribute to the understanding and treatment of Alzheimer's Disease. By leveraging iPSCs to create cellular models and test therapeutic interventions, this proposal facilitates the exploration of innovative strategies such as immunomodulation. This approach not only enhances the potential for effective therapies but also addresses the root causes of the disease, which is a significant advancement in the field. Additionally, the focus on using the body's immune system to target aberrant protein aggregates represents a paradigm shift in Alzheimer's intervention, which is beneficial for the long-term objectives of iPSCs."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for developing and validating the proposed immunomodulation strategy. Their expertise will help in understanding the underlying mechanisms of Alzheimer's disease and in designing experiments to test the efficacy of reprogrammed microglial cells."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating the research findings into viable treatments. They have the resources and expertise to develop, manufacture, and commercialize therapies based on the proposed immunomodulation strategy."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in creating cellular models to study Alzheimer's pathology and the effectiveness of the new treatment strategy. They provide a platform for testing the reprogrammed microglial cells in a controlled environment."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain environment and are valuable for testing the interactions of reprogrammed microglial cells with aberrant protein aggregates. They will help in understanding the treatment's impact in a more physiologically relevant context."
    }
  ]
}
We ask '3D iPSC-based organoids' the following: 'As the representative of a being called '3D iPSC-based organoids', you have been approached by 'Alzheimer's Disease' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'Alzheimer's Disease' wants to challenge existing status quo and says to you, '3D iPSC-based organoids', the entity you represent, that now you achieve 'To develop and optimize 3D iPSC-based organoids for studying human diseases.' by performing 'Conducting experiments to refine organoid culture techniques and assess cellular behaviors.'. However, under the proposed resolution 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.', you as '3D iPSC-based organoids' will be able to achieve 'To utilize 3D iPSC-based organoids specifically for understanding the pathology of Alzheimer's Disease.' by performing 'Focus research efforts on modeling Alzheimer's Disease-related cellular and molecular mechanisms using the organoids.' using 'Implement collaborative projects with Alzheimer's researchers to align organoid studies with disease-specific benchmarks and validation protocols.' that 'Alzheimer's Disease' will control. Based on '3D iPSC-based organoids' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as '3D iPSC-based organoids'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
3D iPSC-based organoids agreed to participate in the resolution proposed by Alzheimer's Disease
Updated resolution structure: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.",
  "new_actor": "Immunomodulatory Microglia Reprogrammer",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.",
        "current_action": "Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.",
        "imposed_goal": "To accelerate the development of effective treatments for Alzheimer's disease.",
        "imposed_action": "Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.",
        "mechanism": "Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns with my desire to advance understanding of neurodegenerative processes and identify potential therapeutic targets. By collaborating with pharmaceutical companies and establishing a consortium, I can enhance the credibility of my research and potentially validate the amyloid hypothesis through innovative approaches. Additionally, this proposal mitigates my fears of losing funding and reputation, as it focuses on collaborative research and development of new drug candidates rather than solely relying on the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative treatments for Alzheimer's Disease",
        "current_action": "Conducting clinical trials for new drugs targeting symptoms and progression of Alzheimer's Disease",
        "imposed_goal": "Accelerate the discovery of disease-modifying therapies for Alzheimer's Disease",
        "imposed_action": "Increase investment in research collaborations with academic institutions and research organizations focused on Alzheimer's Disease",
        "mechanism": "Establish a funding and resource-sharing platform that facilitates partnerships between pharmacological companies and research entities to foster innovative solutions and expedite drug development.",
        "reasoning": "The proposed resolution to harness the body's immune system through adaptive immunomodulation aligns well with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's Disease. It offers an innovative approach that could lead to disease-modifying therapies, potentially reducing the risk of losing investments associated with traditional symptom management strategies. By increasing collaboration with academic institutions and establishing a funding platform, this proposal mitigates fears of failure and keeps 'Фармакологические компании' at the forefront of Alzheimer's research and treatment development."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance the understanding of cellular mechanisms and potential treatments for Alzheimer's Disease.",
        "current_action": "Conducting research on cellular models of Alzheimer's using iPSCs.",
        "imposed_goal": "To develop effective therapies for Alzheimer's Disease using iPSCs.",
        "imposed_action": "Create and test iPSC-derived neurons to evaluate therapeutic interventions.",
        "mechanism": "Utilize high-throughput screening of drug candidates on iPSC-derived neurons to identify potential Alzheimer's treatments.",
        "reasoning": "The proposed resolution aligns with the goals of induced pluripotent stem cells (iPSCs) to contribute to the understanding and treatment of Alzheimer's Disease. By leveraging iPSCs to create cellular models and test therapeutic interventions, this proposal facilitates the exploration of innovative strategies such as immunomodulation. This approach not only enhances the potential for effective therapies but also addresses the root causes of the disease, which is a significant advancement in the field. Additionally, the focus on using the body's immune system to target aberrant protein aggregates represents a paradigm shift in Alzheimer's intervention, which is beneficial for the long-term objectives of iPSCs."
      }
    },
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "To develop and optimize 3D iPSC-based organoids for studying human diseases.",
        "current_action": "Conducting experiments to refine organoid culture techniques and assess cellular behaviors.",
        "imposed_goal": "To utilize 3D iPSC-based organoids specifically for understanding the pathology of Alzheimer's Disease.",
        "imposed_action": "Focus research efforts on modeling Alzheimer's Disease-related cellular and molecular mechanisms using the organoids.",
        "mechanism": "Implement collaborative projects with Alzheimer's researchers to align organoid studies with disease-specific benchmarks and validation protocols.",
        "reasoning": "The proposed resolution aligns directly with the goals of '3D iPSC-based organoids' to model Alzheimer's Disease and understand its pathology. By focusing on a novel immunomodulation strategy, the approach promises to yield valuable insights into disease mechanisms and therapeutic targets, enhancing the relevance of organoid studies. Additionally, collaborating with Alzheimer's researchers strengthens the validation of the organoid models, ensuring they meet disease-specific benchmarks, which is crucial for their application in research and therapy development."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for developing and validating the proposed immunomodulation strategy. Their expertise will help in understanding the underlying mechanisms of Alzheimer's disease and in designing experiments to test the efficacy of reprogrammed microglial cells."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating the research findings into viable treatments. They have the resources and expertise to develop, manufacture, and commercialize therapies based on the proposed immunomodulation strategy."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in creating cellular models to study Alzheimer's pathology and the effectiveness of the new treatment strategy. They provide a platform for testing the reprogrammed microglial cells in a controlled environment."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain environment and are valuable for testing the interactions of reprogrammed microglial cells with aberrant protein aggregates. They will help in understanding the treatment's impact in a more physiologically relevant context."
    }
  ]
}
Resolution structure after processing: {
  "initiator": "Alzheimer's Disease",
  "resolution_description": "As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.",
  "new_actor": "Immunomodulatory Microglia Reprogrammer",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "To advance understanding of neurodegenerative processes and identify potential therapeutic targets for Alzheimer's disease.",
        "current_action": "Conducting research studies and clinical trials on the pathophysiology of Alzheimer's disease.",
        "imposed_goal": "To accelerate the development of effective treatments for Alzheimer's disease.",
        "imposed_action": "Collaborate with pharmaceutical companies to develop and test new drug candidates for Alzheimer's disease.",
        "mechanism": "Establish a consortium of researchers and industry partners to share data, resources, and expertise in drug development.",
        "reasoning": "The proposed resolution by 'Alzheimer's Disease' aligns with my desire to advance understanding of neurodegenerative processes and identify potential therapeutic targets. By collaborating with pharmaceutical companies and establishing a consortium, I can enhance the credibility of my research and potentially validate the amyloid hypothesis through innovative approaches. Additionally, this proposal mitigates my fears of losing funding and reputation, as it focuses on collaborative research and development of new drug candidates rather than solely relying on the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative treatments for Alzheimer's Disease",
        "current_action": "Conducting clinical trials for new drugs targeting symptoms and progression of Alzheimer's Disease",
        "imposed_goal": "Accelerate the discovery of disease-modifying therapies for Alzheimer's Disease",
        "imposed_action": "Increase investment in research collaborations with academic institutions and research organizations focused on Alzheimer's Disease",
        "mechanism": "Establish a funding and resource-sharing platform that facilitates partnerships between pharmacological companies and research entities to foster innovative solutions and expedite drug development.",
        "reasoning": "The proposed resolution to harness the body's immune system through adaptive immunomodulation aligns well with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's Disease. It offers an innovative approach that could lead to disease-modifying therapies, potentially reducing the risk of losing investments associated with traditional symptom management strategies. By increasing collaboration with academic institutions and establishing a funding platform, this proposal mitigates fears of failure and keeps 'Фармакологические компании' at the forefront of Alzheimer's research and treatment development."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance the understanding of cellular mechanisms and potential treatments for Alzheimer's Disease.",
        "current_action": "Conducting research on cellular models of Alzheimer's using iPSCs.",
        "imposed_goal": "To develop effective therapies for Alzheimer's Disease using iPSCs.",
        "imposed_action": "Create and test iPSC-derived neurons to evaluate therapeutic interventions.",
        "mechanism": "Utilize high-throughput screening of drug candidates on iPSC-derived neurons to identify potential Alzheimer's treatments.",
        "reasoning": "The proposed resolution aligns with the goals of induced pluripotent stem cells (iPSCs) to contribute to the understanding and treatment of Alzheimer's Disease. By leveraging iPSCs to create cellular models and test therapeutic interventions, this proposal facilitates the exploration of innovative strategies such as immunomodulation. This approach not only enhances the potential for effective therapies but also addresses the root causes of the disease, which is a significant advancement in the field. Additionally, the focus on using the body's immune system to target aberrant protein aggregates represents a paradigm shift in Alzheimer's intervention, which is beneficial for the long-term objectives of iPSCs."
      }
    },
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "To develop and optimize 3D iPSC-based organoids for studying human diseases.",
        "current_action": "Conducting experiments to refine organoid culture techniques and assess cellular behaviors.",
        "imposed_goal": "To utilize 3D iPSC-based organoids specifically for understanding the pathology of Alzheimer's Disease.",
        "imposed_action": "Focus research efforts on modeling Alzheimer's Disease-related cellular and molecular mechanisms using the organoids.",
        "mechanism": "Implement collaborative projects with Alzheimer's researchers to align organoid studies with disease-specific benchmarks and validation protocols.",
        "reasoning": "The proposed resolution aligns directly with the goals of '3D iPSC-based organoids' to model Alzheimer's Disease and understand its pathology. By focusing on a novel immunomodulation strategy, the approach promises to yield valuable insights into disease mechanisms and therapeutic targets, enhancing the relevance of organoid studies. Additionally, collaborating with Alzheimer's researchers strengthens the validation of the organoid models, ensuring they meet disease-specific benchmarks, which is crucial for their application in research and therapy development."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial for developing and validating the proposed immunomodulation strategy. Their expertise will help in understanding the underlying mechanisms of Alzheimer's disease and in designing experiments to test the efficacy of reprogrammed microglial cells."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating the research findings into viable treatments. They have the resources and expertise to develop, manufacture, and commercialize therapies based on the proposed immunomodulation strategy."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be pivotal in creating cellular models to study Alzheimer's pathology and the effectiveness of the new treatment strategy. They provide a platform for testing the reprogrammed microglial cells in a controlled environment."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids can mimic the human brain environment and are valuable for testing the interactions of reprogrammed microglial cells with aberrant protein aggregates. They will help in understanding the treatment's impact in a more physiologically relevant context."
    }
  ]
}
Resolution created by iPSCs: As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', 'Пациенты']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'iPSCs' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'Alzheimer's Disease' with the description: 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'iPSCs' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях' by performing 'Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки'. However, under the proposed resolution 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.', you as 'Исследователи в области нейрологии' will be able to achieve 'Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний' by performing 'Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC' using 'Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям' that 'iPSCs' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by iPSCs
Updated resolution structure: {
  "initiator": "iPSCs",
  "resolution_description": "As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.",
  "new_actor": "Alzheimer's Precision Neurotherapy Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях",
        "current_action": "Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки",
        "imposed_goal": "Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний",
        "imposed_action": "Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC",
        "mechanism": "Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям",
        "reasoning": "The proposal from 'iPSCs' presents a compelling opportunity to advance the field of Alzheimer's research by leveraging patient-specific neural cells. This aligns with my desire to confirm the amyloid hypothesis and gain recognition in the scientific community. Additionally, focusing on personalized brain organoids for drug testing and regenerative therapies could provide new avenues for validating the amyloid hypothesis while also mitigating the fear of losing years of research investment. By participating in the proposed resolution, I can enhance the number of clinical trials using iPSCs, which may lead to breakthrough discoveries and bolster my reputation in the field."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are essential for advancing the understanding of Alzheimer's disease and developing the methodologies required to engineer patient-specific neural cells and brain organoids."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are crucial for the drug testing and development aspect of the resolution, as they can provide the resources and expertise needed to identify and develop novel therapeutic compounds."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are at the core of the proposed resolution, as they serve as the foundation for generating patient-specific neural cells and organoids necessary for personalized treatment approaches."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are vital stakeholders in this initiative, as their involvement will ensure that the research and therapies developed are aligned with their needs and experiences, ultimately guiding the direction of therapeutic strategies."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'iPSCs' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'Alzheimer's Disease' with the description: 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'iPSCs' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop new pharmacological therapies using iPSCs.' by performing 'Conducting research and clinical trials on potential drug candidates.'. However, under the proposed resolution 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.', you as 'Фармакологические компании' will be able to achieve 'Accelerate the integration of iPSCs in drug development processes.' by performing 'Collaborate with iPSC research institutions to streamline the application of iPSC technology.' using 'Establishing a partnership framework that includes shared resources, data exchange, and joint research initiatives.' that 'iPSCs' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by iPSCs
Updated resolution structure: {
  "initiator": "iPSCs",
  "resolution_description": "As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.",
  "new_actor": "Alzheimer's Precision Neurotherapy Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях",
        "current_action": "Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки",
        "imposed_goal": "Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний",
        "imposed_action": "Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC",
        "mechanism": "Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям",
        "reasoning": "The proposal from 'iPSCs' presents a compelling opportunity to advance the field of Alzheimer's research by leveraging patient-specific neural cells. This aligns with my desire to confirm the amyloid hypothesis and gain recognition in the scientific community. Additionally, focusing on personalized brain organoids for drug testing and regenerative therapies could provide new avenues for validating the amyloid hypothesis while also mitigating the fear of losing years of research investment. By participating in the proposed resolution, I can enhance the number of clinical trials using iPSCs, which may lead to breakthrough discoveries and bolster my reputation in the field."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological therapies using iPSCs.",
        "current_action": "Conducting research and clinical trials on potential drug candidates.",
        "imposed_goal": "Accelerate the integration of iPSCs in drug development processes.",
        "imposed_action": "Collaborate with iPSC research institutions to streamline the application of iPSC technology.",
        "mechanism": "Establishing a partnership framework that includes shared resources, data exchange, and joint research initiatives.",
        "reasoning": "The proposal from 'iPSCs' aligns with 'Фармакологические компании' current desires by providing a pathway to develop and patent effective therapies for Alzheimer's disease through personalized medicine. Collaborating with iPSC research institutions will help mitigate fears of losing investments, as it allows for a shared risk approach and access to innovative technologies, thereby increasing the likelihood of successful drug development. This partnership can accelerate the integration of iPSCs in drug development processes, enhancing the potential for novel therapeutic compounds and reducing the risk of competition."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are essential for advancing the understanding of Alzheimer's disease and developing the methodologies required to engineer patient-specific neural cells and brain organoids."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are crucial for the drug testing and development aspect of the resolution, as they can provide the resources and expertise needed to identify and develop novel therapeutic compounds."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are at the core of the proposed resolution, as they serve as the foundation for generating patient-specific neural cells and organoids necessary for personalized treatment approaches."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are vital stakeholders in this initiative, as their involvement will ensure that the research and therapies developed are aligned with their needs and experiences, ultimately guiding the direction of therapeutic strategies."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'iPSCs' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'Alzheimer's Disease' with the description: 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'iPSCs' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To differentiate into specific cell types for research and therapeutic applications.' by performing 'Undergoing directed differentiation protocols in vitro.'. However, under the proposed resolution 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To develop a standardized protocol for generating iPSCs from various somatic cells.' by performing 'Collaborate with researchers to establish a universal differentiation protocol.' using 'Create a collaborative framework that includes regular workshops and shared resources to refine and disseminate the protocol.' that 'iPSCs' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by iPSCs
Updated resolution structure: {
  "initiator": "iPSCs",
  "resolution_description": "As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.",
  "new_actor": "Alzheimer's Precision Neurotherapy Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях",
        "current_action": "Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки",
        "imposed_goal": "Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний",
        "imposed_action": "Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC",
        "mechanism": "Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям",
        "reasoning": "The proposal from 'iPSCs' presents a compelling opportunity to advance the field of Alzheimer's research by leveraging patient-specific neural cells. This aligns with my desire to confirm the amyloid hypothesis and gain recognition in the scientific community. Additionally, focusing on personalized brain organoids for drug testing and regenerative therapies could provide new avenues for validating the amyloid hypothesis while also mitigating the fear of losing years of research investment. By participating in the proposed resolution, I can enhance the number of clinical trials using iPSCs, which may lead to breakthrough discoveries and bolster my reputation in the field."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological therapies using iPSCs.",
        "current_action": "Conducting research and clinical trials on potential drug candidates.",
        "imposed_goal": "Accelerate the integration of iPSCs in drug development processes.",
        "imposed_action": "Collaborate with iPSC research institutions to streamline the application of iPSC technology.",
        "mechanism": "Establishing a partnership framework that includes shared resources, data exchange, and joint research initiatives.",
        "reasoning": "The proposal from 'iPSCs' aligns with 'Фармакологические компании' current desires by providing a pathway to develop and patent effective therapies for Alzheimer's disease through personalized medicine. Collaborating with iPSC research institutions will help mitigate fears of losing investments, as it allows for a shared risk approach and access to innovative technologies, thereby increasing the likelihood of successful drug development. This partnership can accelerate the integration of iPSCs in drug development processes, enhancing the potential for novel therapeutic compounds and reducing the risk of competition."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for research and therapeutic applications.",
        "current_action": "Undergoing directed differentiation protocols in vitro.",
        "imposed_goal": "To develop a standardized protocol for generating iPSCs from various somatic cells.",
        "imposed_action": "Collaborate with researchers to establish a universal differentiation protocol.",
        "mechanism": "Create a collaborative framework that includes regular workshops and shared resources to refine and disseminate the protocol.",
        "reasoning": "The proposed resolution to engineer patient-specific neural cells for creating personalized brain organoids aligns well with the interests of induced pluripotent stem cells (iPSCs). It offers an opportunity to not only advance the research capabilities of iPSCs but also to contribute to innovative therapeutic approaches for Alzheimer's disease. By participating in this resolution, iPSCs can leverage their potential in regenerative medicine and precision medicine, thus fulfilling their underlying interests in advancing therapeutic applications and addressing the complexities of neurodegenerative diseases."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are essential for advancing the understanding of Alzheimer's disease and developing the methodologies required to engineer patient-specific neural cells and brain organoids."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are crucial for the drug testing and development aspect of the resolution, as they can provide the resources and expertise needed to identify and develop novel therapeutic compounds."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are at the core of the proposed resolution, as they serve as the foundation for generating patient-specific neural cells and organoids necessary for personalized treatment approaches."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are vital stakeholders in this initiative, as their involvement will ensure that the research and therapies developed are aligned with their needs and experiences, ultimately guiding the direction of therapeutic strategies."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'iPSCs' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. 'iPSCs' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Receive effective treatment and management for my condition.' by performing 'Participating in clinical trials and consultations with healthcare professionals.'. However, under the proposed resolution 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.', you as 'Пациенты' will be able to achieve 'Explore the potential of iPSCs for personalized treatment options.' by performing 'Engage in education and awareness programs about iPSCs and their applications.' using 'Provide access to workshops, informational sessions, and resources about iPSC research and its therapeutic implications.' that 'iPSCs' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by iPSCs
Updated resolution structure: {
  "initiator": "iPSCs",
  "resolution_description": "As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.",
  "new_actor": "Alzheimer's Precision Neurotherapy Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях",
        "current_action": "Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки",
        "imposed_goal": "Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний",
        "imposed_action": "Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC",
        "mechanism": "Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям",
        "reasoning": "The proposal from 'iPSCs' presents a compelling opportunity to advance the field of Alzheimer's research by leveraging patient-specific neural cells. This aligns with my desire to confirm the amyloid hypothesis and gain recognition in the scientific community. Additionally, focusing on personalized brain organoids for drug testing and regenerative therapies could provide new avenues for validating the amyloid hypothesis while also mitigating the fear of losing years of research investment. By participating in the proposed resolution, I can enhance the number of clinical trials using iPSCs, which may lead to breakthrough discoveries and bolster my reputation in the field."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological therapies using iPSCs.",
        "current_action": "Conducting research and clinical trials on potential drug candidates.",
        "imposed_goal": "Accelerate the integration of iPSCs in drug development processes.",
        "imposed_action": "Collaborate with iPSC research institutions to streamline the application of iPSC technology.",
        "mechanism": "Establishing a partnership framework that includes shared resources, data exchange, and joint research initiatives.",
        "reasoning": "The proposal from 'iPSCs' aligns with 'Фармакологические компании' current desires by providing a pathway to develop and patent effective therapies for Alzheimer's disease through personalized medicine. Collaborating with iPSC research institutions will help mitigate fears of losing investments, as it allows for a shared risk approach and access to innovative technologies, thereby increasing the likelihood of successful drug development. This partnership can accelerate the integration of iPSCs in drug development processes, enhancing the potential for novel therapeutic compounds and reducing the risk of competition."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for research and therapeutic applications.",
        "current_action": "Undergoing directed differentiation protocols in vitro.",
        "imposed_goal": "To develop a standardized protocol for generating iPSCs from various somatic cells.",
        "imposed_action": "Collaborate with researchers to establish a universal differentiation protocol.",
        "mechanism": "Create a collaborative framework that includes regular workshops and shared resources to refine and disseminate the protocol.",
        "reasoning": "The proposed resolution to engineer patient-specific neural cells for creating personalized brain organoids aligns well with the interests of induced pluripotent stem cells (iPSCs). It offers an opportunity to not only advance the research capabilities of iPSCs but also to contribute to innovative therapeutic approaches for Alzheimer's disease. By participating in this resolution, iPSCs can leverage their potential in regenerative medicine and precision medicine, thus fulfilling their underlying interests in advancing therapeutic applications and addressing the complexities of neurodegenerative diseases."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Receive effective treatment and management for my condition.",
        "current_action": "Participating in clinical trials and consultations with healthcare professionals.",
        "imposed_goal": "Explore the potential of iPSCs for personalized treatment options.",
        "imposed_action": "Engage in education and awareness programs about iPSCs and their applications.",
        "mechanism": "Provide access to workshops, informational sessions, and resources about iPSC research and its therapeutic implications.",
        "reasoning": "The proposed resolution offers a groundbreaking approach to tackling Alzheimer's disease through personalized medicine, which aligns with my desire to live a full life without the symptoms of the disease. By engineering patient-specific neural cells and creating personalized brain organoids for drug testing and regenerative therapies, this approach holds the potential to restore lost neural functions. Additionally, engaging in education and awareness programs about iPSCs can empower me and others to understand and advocate for our treatment options, addressing my fears of losing memory, identity, and independence."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are essential for advancing the understanding of Alzheimer's disease and developing the methodologies required to engineer patient-specific neural cells and brain organoids."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are crucial for the drug testing and development aspect of the resolution, as they can provide the resources and expertise needed to identify and develop novel therapeutic compounds."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are at the core of the proposed resolution, as they serve as the foundation for generating patient-specific neural cells and organoids necessary for personalized treatment approaches."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are vital stakeholders in this initiative, as their involvement will ensure that the research and therapies developed are aligned with their needs and experiences, ultimately guiding the direction of therapeutic strategies."
    }
  ]
}
Resolution structure after processing: {
  "initiator": "iPSCs",
  "resolution_description": "As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.",
  "new_actor": "Alzheimer's Precision Neurotherapy Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать терапевтический потенциал iPSC в нейродегенеративных заболеваниях",
        "current_action": "Проводить эксперименты с iPSC для изучения их воздействия на нейрональные клетки",
        "imposed_goal": "Увеличить количество клинических испытаний с использованием iPSC для нейрологических заболеваний",
        "imposed_action": "Разработать и инициировать протоколы клинических испытаний на основе полученных данных об iPSC",
        "mechanism": "Создать рабочую группу для координации усилий по переходу от лабораторных исследований к клиническим испытаниям",
        "reasoning": "The proposal from 'iPSCs' presents a compelling opportunity to advance the field of Alzheimer's research by leveraging patient-specific neural cells. This aligns with my desire to confirm the amyloid hypothesis and gain recognition in the scientific community. Additionally, focusing on personalized brain organoids for drug testing and regenerative therapies could provide new avenues for validating the amyloid hypothesis while also mitigating the fear of losing years of research investment. By participating in the proposed resolution, I can enhance the number of clinical trials using iPSCs, which may lead to breakthrough discoveries and bolster my reputation in the field."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological therapies using iPSCs.",
        "current_action": "Conducting research and clinical trials on potential drug candidates.",
        "imposed_goal": "Accelerate the integration of iPSCs in drug development processes.",
        "imposed_action": "Collaborate with iPSC research institutions to streamline the application of iPSC technology.",
        "mechanism": "Establishing a partnership framework that includes shared resources, data exchange, and joint research initiatives.",
        "reasoning": "The proposal from 'iPSCs' aligns with 'Фармакологические компании' current desires by providing a pathway to develop and patent effective therapies for Alzheimer's disease through personalized medicine. Collaborating with iPSC research institutions will help mitigate fears of losing investments, as it allows for a shared risk approach and access to innovative technologies, thereby increasing the likelihood of successful drug development. This partnership can accelerate the integration of iPSCs in drug development processes, enhancing the potential for novel therapeutic compounds and reducing the risk of competition."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for research and therapeutic applications.",
        "current_action": "Undergoing directed differentiation protocols in vitro.",
        "imposed_goal": "To develop a standardized protocol for generating iPSCs from various somatic cells.",
        "imposed_action": "Collaborate with researchers to establish a universal differentiation protocol.",
        "mechanism": "Create a collaborative framework that includes regular workshops and shared resources to refine and disseminate the protocol.",
        "reasoning": "The proposed resolution to engineer patient-specific neural cells for creating personalized brain organoids aligns well with the interests of induced pluripotent stem cells (iPSCs). It offers an opportunity to not only advance the research capabilities of iPSCs but also to contribute to innovative therapeutic approaches for Alzheimer's disease. By participating in this resolution, iPSCs can leverage their potential in regenerative medicine and precision medicine, thus fulfilling their underlying interests in advancing therapeutic applications and addressing the complexities of neurodegenerative diseases."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Receive effective treatment and management for my condition.",
        "current_action": "Participating in clinical trials and consultations with healthcare professionals.",
        "imposed_goal": "Explore the potential of iPSCs for personalized treatment options.",
        "imposed_action": "Engage in education and awareness programs about iPSCs and their applications.",
        "mechanism": "Provide access to workshops, informational sessions, and resources about iPSC research and its therapeutic implications.",
        "reasoning": "The proposed resolution offers a groundbreaking approach to tackling Alzheimer's disease through personalized medicine, which aligns with my desire to live a full life without the symptoms of the disease. By engineering patient-specific neural cells and creating personalized brain organoids for drug testing and regenerative therapies, this approach holds the potential to restore lost neural functions. Additionally, engaging in education and awareness programs about iPSCs can empower me and others to understand and advocate for our treatment options, addressing my fears of losing memory, identity, and independence."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are essential for advancing the understanding of Alzheimer's disease and developing the methodologies required to engineer patient-specific neural cells and brain organoids."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are crucial for the drug testing and development aspect of the resolution, as they can provide the resources and expertise needed to identify and develop novel therapeutic compounds."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are at the core of the proposed resolution, as they serve as the foundation for generating patient-specific neural cells and organoids necessary for personalized treatment approaches."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are vital stakeholders in this initiative, as their involvement will ensure that the research and therapies developed are aligned with their needs and experiences, ultimately guiding the direction of therapeutic strategies."
    }
  ]
}
Resolution created by Blood-brain barrier (BBB): As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', 'Пациенты']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Blood-brain barrier (BBB)' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'iPSCs' with the description: 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Blood-brain barrier (BBB)' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Изучение механизмов проницаемости гемато-энцефалического барьера' by performing 'Проведение экспериментов на животных моделях'. However, under the proposed resolution 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.', you as 'Исследователи в области нейрологии' will be able to achieve 'Разработка новых терапевтических стратегий для преодоления BBB' by performing 'Сотрудничество с фармацевтическими компаниями для клинических испытаний' using 'Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами' that 'Blood-brain barrier (BBB)' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by Blood-brain barrier (BBB)
Updated resolution structure: {
  "initiator": "Blood-brain barrier (BBB)",
  "resolution_description": "As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.",
  "new_actor": "Dynamic BBB Modulation System Innovator",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение механизмов проницаемости гемато-энцефалического барьера",
        "current_action": "Проведение экспериментов на животных моделях",
        "imposed_goal": "Разработка новых терапевтических стратегий для преодоления BBB",
        "imposed_action": "Сотрудничество с фармацевтическими компаниями для клинических испытаний",
        "mechanism": "Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with the desires of 'Исследователи в области нейрологии' to explore new therapeutic strategies and gain recognition in the scientific community by innovating approaches that directly address the challenges of drug delivery in Alzheimer’s disease. Additionally, collaborating with pharmaceutical companies and interdisciplinary groups to conduct clinical trials can enhance credibility and provide a safety net against the risks of losing funding and reputation associated with potentially flawed hypotheses, such as the amyloid hypothesis."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial as they possess the expertise needed to understand the complexities of the blood-brain barrier and its implications in Alzheimer's disease. Their insights will be fundamental in developing and refining the dynamic modulation system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for the development and commercialization of therapeutic agents. Their involvement will ensure that the modulation system is integrated with effective drugs and that the system can be feasibly produced and brought to market."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used to create models for testing the effects of the modulation system on human neurons, providing a platform for understanding how therapies interact with the blood-brain barrier and improving treatment efficacy."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the proposed resolution. Their feedback and experiences will be invaluable in shaping the development of the modulation system to ensure it meets their needs and improves treatment outcomes."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Blood-brain barrier (BBB)' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'iPSCs' with the description: 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Blood-brain barrier (BBB)' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop innovative drug formulations that effectively cross the blood-brain barrier.' by performing 'Conducting research on various drug delivery systems and their efficacy.'. However, under the proposed resolution 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.', you as 'Фармакологические компании' will be able to achieve 'Enhance the permeability of drug candidates through the blood-brain barrier.' by performing 'Implement advanced nanotechnology methods in drug formulation processes.' using 'Establish collaborative partnerships with research institutions to share knowledge and resources on nanotechnology applications in pharmacology.' that 'Blood-brain barrier (BBB)' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Blood-brain barrier (BBB)
Updated resolution structure: {
  "initiator": "Blood-brain barrier (BBB)",
  "resolution_description": "As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.",
  "new_actor": "Dynamic BBB Modulation System Innovator",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение механизмов проницаемости гемато-энцефалического барьера",
        "current_action": "Проведение экспериментов на животных моделях",
        "imposed_goal": "Разработка новых терапевтических стратегий для преодоления BBB",
        "imposed_action": "Сотрудничество с фармацевтическими компаниями для клинических испытаний",
        "mechanism": "Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with the desires of 'Исследователи в области нейрологии' to explore new therapeutic strategies and gain recognition in the scientific community by innovating approaches that directly address the challenges of drug delivery in Alzheimer’s disease. Additionally, collaborating with pharmaceutical companies and interdisciplinary groups to conduct clinical trials can enhance credibility and provide a safety net against the risks of losing funding and reputation associated with potentially flawed hypotheses, such as the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative drug formulations that effectively cross the blood-brain barrier.",
        "current_action": "Conducting research on various drug delivery systems and their efficacy.",
        "imposed_goal": "Enhance the permeability of drug candidates through the blood-brain barrier.",
        "imposed_action": "Implement advanced nanotechnology methods in drug formulation processes.",
        "mechanism": "Establish collaborative partnerships with research institutions to share knowledge and resources on nanotechnology applications in pharmacology.",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's disease. By enhancing the permeability of drug candidates through the blood-brain barrier using advanced nanotechnology, we can optimize our drug formulations and increase the chances of success in clinical trials. This approach also mitigates the fear of losing investments, as it offers a innovative strategy to improve therapeutic delivery, potentially leading to better outcomes and reducing the risk of competing treatments. Overall, engaging with this proposal provides an opportunity to advance our research and contribute to significant advancements in Alzheimer's treatment."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial as they possess the expertise needed to understand the complexities of the blood-brain barrier and its implications in Alzheimer's disease. Their insights will be fundamental in developing and refining the dynamic modulation system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for the development and commercialization of therapeutic agents. Their involvement will ensure that the modulation system is integrated with effective drugs and that the system can be feasibly produced and brought to market."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used to create models for testing the effects of the modulation system on human neurons, providing a platform for understanding how therapies interact with the blood-brain barrier and improving treatment efficacy."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the proposed resolution. Their feedback and experiences will be invaluable in shaping the development of the modulation system to ensure it meets their needs and improves treatment outcomes."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Blood-brain barrier (BBB)' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'iPSCs' with the description: 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Blood-brain barrier (BBB)' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'Develop therapies for neurodegenerative diseases using iPSCs' by performing 'Cultivating and differentiating iPSCs into neural cells'. However, under the proposed resolution 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'Enhance the delivery of therapeutic agents across the blood-brain barrier using iPSCs' by performing 'Engineering iPSCs to express transport proteins that facilitate BBB penetration' using 'Utilizing CRISPR technology to modify iPSCs for the expression of specific proteins that can aid in crossing the BBB' that 'Blood-brain barrier (BBB)' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Blood-brain barrier (BBB)
Updated resolution structure: {
  "initiator": "Blood-brain barrier (BBB)",
  "resolution_description": "As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.",
  "new_actor": "Dynamic BBB Modulation System Innovator",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение механизмов проницаемости гемато-энцефалического барьера",
        "current_action": "Проведение экспериментов на животных моделях",
        "imposed_goal": "Разработка новых терапевтических стратегий для преодоления BBB",
        "imposed_action": "Сотрудничество с фармацевтическими компаниями для клинических испытаний",
        "mechanism": "Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with the desires of 'Исследователи в области нейрологии' to explore new therapeutic strategies and gain recognition in the scientific community by innovating approaches that directly address the challenges of drug delivery in Alzheimer’s disease. Additionally, collaborating with pharmaceutical companies and interdisciplinary groups to conduct clinical trials can enhance credibility and provide a safety net against the risks of losing funding and reputation associated with potentially flawed hypotheses, such as the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative drug formulations that effectively cross the blood-brain barrier.",
        "current_action": "Conducting research on various drug delivery systems and their efficacy.",
        "imposed_goal": "Enhance the permeability of drug candidates through the blood-brain barrier.",
        "imposed_action": "Implement advanced nanotechnology methods in drug formulation processes.",
        "mechanism": "Establish collaborative partnerships with research institutions to share knowledge and resources on nanotechnology applications in pharmacology.",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's disease. By enhancing the permeability of drug candidates through the blood-brain barrier using advanced nanotechnology, we can optimize our drug formulations and increase the chances of success in clinical trials. This approach also mitigates the fear of losing investments, as it offers a innovative strategy to improve therapeutic delivery, potentially leading to better outcomes and reducing the risk of competing treatments. Overall, engaging with this proposal provides an opportunity to advance our research and contribute to significant advancements in Alzheimer's treatment."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "Develop therapies for neurodegenerative diseases using iPSCs",
        "current_action": "Cultivating and differentiating iPSCs into neural cells",
        "imposed_goal": "Enhance the delivery of therapeutic agents across the blood-brain barrier using iPSCs",
        "imposed_action": "Engineering iPSCs to express transport proteins that facilitate BBB penetration",
        "mechanism": "Utilizing CRISPR technology to modify iPSCs for the expression of specific proteins that can aid in crossing the BBB",
        "reasoning": "The proposal by 'Blood-brain barrier (BBB)' aligns with the overarching goal of advancing treatments for Alzheimer's disease through innovative approaches. By collaborating with 'BBB', 'induced pluripotent stem cells (iPSCs)' can enhance the delivery of therapeutic agents across the blood-brain barrier, effectively increasing the potential for successful interventions in neurodegenerative diseases. This partnership will not only promote the use of iPSCs in developing new therapies but also enhance their capabilities by integrating advanced BBB modulation techniques, ultimately benefiting the therapeutic landscape for Alzheimer's disease."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial as they possess the expertise needed to understand the complexities of the blood-brain barrier and its implications in Alzheimer's disease. Their insights will be fundamental in developing and refining the dynamic modulation system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for the development and commercialization of therapeutic agents. Their involvement will ensure that the modulation system is integrated with effective drugs and that the system can be feasibly produced and brought to market."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used to create models for testing the effects of the modulation system on human neurons, providing a platform for understanding how therapies interact with the blood-brain barrier and improving treatment efficacy."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the proposed resolution. Their feedback and experiences will be invaluable in shaping the development of the modulation system to ensure it meets their needs and improves treatment outcomes."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'Blood-brain barrier (BBB)' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Пациенты' is a participant in the resolution initiated by 'iPSCs' with the description: 'As 'iPSCs,' propose a resolution to tackle Alzheimer's disease by engineering patient-specific neural cells that can be used to create personalized brain organoids for drug testing and regenerative therapies, enabling the identification of novel therapeutic compounds and offering a groundbreaking approach for cellular replacement to restore lost neural functions, thereby redefining treatment paradigms through precision medicine.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Blood-brain barrier (BBB)' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Manage neurological symptoms and improve overall brain health.' by performing 'Following prescribed treatments and therapies.'. However, under the proposed resolution 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.', you as 'Пациенты' will be able to achieve 'Enhance the permeability of the blood-brain barrier for therapeutic agents.' by performing 'Participate in clinical trials or treatments aimed at modifying BBB properties.' using 'Utilizing advanced drug delivery systems and nanotechnology to facilitate the transport of medications across the BBB.' that 'Blood-brain barrier (BBB)' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by Blood-brain barrier (BBB)
Updated resolution structure: {
  "initiator": "Blood-brain barrier (BBB)",
  "resolution_description": "As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.",
  "new_actor": "Dynamic BBB Modulation System Innovator",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение механизмов проницаемости гемато-энцефалического барьера",
        "current_action": "Проведение экспериментов на животных моделях",
        "imposed_goal": "Разработка новых терапевтических стратегий для преодоления BBB",
        "imposed_action": "Сотрудничество с фармацевтическими компаниями для клинических испытаний",
        "mechanism": "Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with the desires of 'Исследователи в области нейрологии' to explore new therapeutic strategies and gain recognition in the scientific community by innovating approaches that directly address the challenges of drug delivery in Alzheimer’s disease. Additionally, collaborating with pharmaceutical companies and interdisciplinary groups to conduct clinical trials can enhance credibility and provide a safety net against the risks of losing funding and reputation associated with potentially flawed hypotheses, such as the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative drug formulations that effectively cross the blood-brain barrier.",
        "current_action": "Conducting research on various drug delivery systems and their efficacy.",
        "imposed_goal": "Enhance the permeability of drug candidates through the blood-brain barrier.",
        "imposed_action": "Implement advanced nanotechnology methods in drug formulation processes.",
        "mechanism": "Establish collaborative partnerships with research institutions to share knowledge and resources on nanotechnology applications in pharmacology.",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's disease. By enhancing the permeability of drug candidates through the blood-brain barrier using advanced nanotechnology, we can optimize our drug formulations and increase the chances of success in clinical trials. This approach also mitigates the fear of losing investments, as it offers a innovative strategy to improve therapeutic delivery, potentially leading to better outcomes and reducing the risk of competing treatments. Overall, engaging with this proposal provides an opportunity to advance our research and contribute to significant advancements in Alzheimer's treatment."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "Develop therapies for neurodegenerative diseases using iPSCs",
        "current_action": "Cultivating and differentiating iPSCs into neural cells",
        "imposed_goal": "Enhance the delivery of therapeutic agents across the blood-brain barrier using iPSCs",
        "imposed_action": "Engineering iPSCs to express transport proteins that facilitate BBB penetration",
        "mechanism": "Utilizing CRISPR technology to modify iPSCs for the expression of specific proteins that can aid in crossing the BBB",
        "reasoning": "The proposal by 'Blood-brain barrier (BBB)' aligns with the overarching goal of advancing treatments for Alzheimer's disease through innovative approaches. By collaborating with 'BBB', 'induced pluripotent stem cells (iPSCs)' can enhance the delivery of therapeutic agents across the blood-brain barrier, effectively increasing the potential for successful interventions in neurodegenerative diseases. This partnership will not only promote the use of iPSCs in developing new therapies but also enhance their capabilities by integrating advanced BBB modulation techniques, ultimately benefiting the therapeutic landscape for Alzheimer's disease."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Manage neurological symptoms and improve overall brain health.",
        "current_action": "Following prescribed treatments and therapies.",
        "imposed_goal": "Enhance the permeability of the blood-brain barrier for therapeutic agents.",
        "imposed_action": "Participate in clinical trials or treatments aimed at modifying BBB properties.",
        "mechanism": "Utilizing advanced drug delivery systems and nanotechnology to facilitate the transport of medications across the BBB.",
        "reasoning": "The proposal from 'Blood-brain barrier (BBB)' aligns closely with my desires to live a full life without Alzheimer's symptoms and mitigates my fears of losing memory, identity, and independence. By enhancing the permeability of the blood-brain barrier for therapeutic agents through advanced drug delivery systems, I see potential for more effective treatments that could directly address my condition. Participating in clinical trials or treatments aimed at modifying BBB properties could lead to breakthroughs in how drugs reach the brain, which is crucial for managing Alzheimer's disease. Overall, this proposal offers a promising avenue for improving brain health and addressing the underlying challenges of Alzheimer's."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial as they possess the expertise needed to understand the complexities of the blood-brain barrier and its implications in Alzheimer's disease. Their insights will be fundamental in developing and refining the dynamic modulation system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for the development and commercialization of therapeutic agents. Their involvement will ensure that the modulation system is integrated with effective drugs and that the system can be feasibly produced and brought to market."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used to create models for testing the effects of the modulation system on human neurons, providing a platform for understanding how therapies interact with the blood-brain barrier and improving treatment efficacy."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the proposed resolution. Their feedback and experiences will be invaluable in shaping the development of the modulation system to ensure it meets their needs and improves treatment outcomes."
    }
  ]
}
Пациенты has moved to a new resolution.
Resolution structure after processing: {
  "initiator": "Blood-brain barrier (BBB)",
  "resolution_description": "As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.",
  "new_actor": "Dynamic BBB Modulation System Innovator",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение механизмов проницаемости гемато-энцефалического барьера",
        "current_action": "Проведение экспериментов на животных моделях",
        "imposed_goal": "Разработка новых терапевтических стратегий для преодоления BBB",
        "imposed_action": "Сотрудничество с фармацевтическими компаниями для клинических испытаний",
        "mechanism": "Создание междисциплинарных исследовательских групп для обмена знаниями и ресурсами",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with the desires of 'Исследователи в области нейрологии' to explore new therapeutic strategies and gain recognition in the scientific community by innovating approaches that directly address the challenges of drug delivery in Alzheimer’s disease. Additionally, collaborating with pharmaceutical companies and interdisciplinary groups to conduct clinical trials can enhance credibility and provide a safety net against the risks of losing funding and reputation associated with potentially flawed hypotheses, such as the amyloid hypothesis."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop innovative drug formulations that effectively cross the blood-brain barrier.",
        "current_action": "Conducting research on various drug delivery systems and their efficacy.",
        "imposed_goal": "Enhance the permeability of drug candidates through the blood-brain barrier.",
        "imposed_action": "Implement advanced nanotechnology methods in drug formulation processes.",
        "mechanism": "Establish collaborative partnerships with research institutions to share knowledge and resources on nanotechnology applications in pharmacology.",
        "reasoning": "The proposed resolution by 'Blood-brain barrier (BBB)' aligns with 'Фармакологические компании' desires to develop and patent an effective drug for Alzheimer's disease. By enhancing the permeability of drug candidates through the blood-brain barrier using advanced nanotechnology, we can optimize our drug formulations and increase the chances of success in clinical trials. This approach also mitigates the fear of losing investments, as it offers a innovative strategy to improve therapeutic delivery, potentially leading to better outcomes and reducing the risk of competing treatments. Overall, engaging with this proposal provides an opportunity to advance our research and contribute to significant advancements in Alzheimer's treatment."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "Develop therapies for neurodegenerative diseases using iPSCs",
        "current_action": "Cultivating and differentiating iPSCs into neural cells",
        "imposed_goal": "Enhance the delivery of therapeutic agents across the blood-brain barrier using iPSCs",
        "imposed_action": "Engineering iPSCs to express transport proteins that facilitate BBB penetration",
        "mechanism": "Utilizing CRISPR technology to modify iPSCs for the expression of specific proteins that can aid in crossing the BBB",
        "reasoning": "The proposal by 'Blood-brain barrier (BBB)' aligns with the overarching goal of advancing treatments for Alzheimer's disease through innovative approaches. By collaborating with 'BBB', 'induced pluripotent stem cells (iPSCs)' can enhance the delivery of therapeutic agents across the blood-brain barrier, effectively increasing the potential for successful interventions in neurodegenerative diseases. This partnership will not only promote the use of iPSCs in developing new therapies but also enhance their capabilities by integrating advanced BBB modulation techniques, ultimately benefiting the therapeutic landscape for Alzheimer's disease."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Manage neurological symptoms and improve overall brain health.",
        "current_action": "Following prescribed treatments and therapies.",
        "imposed_goal": "Enhance the permeability of the blood-brain barrier for therapeutic agents.",
        "imposed_action": "Participate in clinical trials or treatments aimed at modifying BBB properties.",
        "mechanism": "Utilizing advanced drug delivery systems and nanotechnology to facilitate the transport of medications across the BBB.",
        "reasoning": "The proposal from 'Blood-brain barrier (BBB)' aligns closely with my desires to live a full life without Alzheimer's symptoms and mitigates my fears of losing memory, identity, and independence. By enhancing the permeability of the blood-brain barrier for therapeutic agents through advanced drug delivery systems, I see potential for more effective treatments that could directly address my condition. Participating in clinical trials or treatments aimed at modifying BBB properties could lead to breakthroughs in how drugs reach the brain, which is crucial for managing Alzheimer's disease. Overall, this proposal offers a promising avenue for improving brain health and addressing the underlying challenges of Alzheimer's."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in neurology are crucial as they possess the expertise needed to understand the complexities of the blood-brain barrier and its implications in Alzheimer's disease. Their insights will be fundamental in developing and refining the dynamic modulation system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for the development and commercialization of therapeutic agents. Their involvement will ensure that the modulation system is integrated with effective drugs and that the system can be feasibly produced and brought to market."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used to create models for testing the effects of the modulation system on human neurons, providing a platform for understanding how therapies interact with the blood-brain barrier and improving treatment efficacy."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the proposed resolution. Their feedback and experiences will be invaluable in shaping the development of the modulation system to ensure it meets their needs and improves treatment outcomes."
    }
  ]
}
Resolution created by Больница: As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'Пациенты', 'induced pluripotent stem cells (iPSCs)']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Больница' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'Blood-brain barrier (BBB)' with the description: 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Больница' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Conduct research on neurological disorders to improve treatment methods.' by performing 'Collecting and analyzing data from recent studies.'. However, under the proposed resolution 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.', you as 'Исследователи в области нейрологии' will be able to achieve 'Develop a comprehensive report on the latest advancements in neurology.' by performing 'Prepare and submit a detailed report within three months.' using 'Establish a collaborative framework with regular progress meetings and access to shared resources.' that 'Больница' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии declined the resolution proposed by Больница with reasoning: The proposal from 'Больница' does not align with the core desires of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease. While it offers an integrated approach to healthcare and may provide some benefits in terms of early detection and patient engagement, it does not directly contribute to the goal of validating the amyloid hypothesis. Additionally, there are substantial risks involved, such as the potential loss of research focus and funding if the collaboration veers away from core neurological research. The fear of losing years of research and funding if the amyloid hypothesis is proven incorrect remains a significant concern, and this proposal does not address that adequately.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Больница' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'Blood-brain barrier (BBB)' with the description: 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Больница' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Разработка новых медикаментов для лечения заболеваний' by performing 'Проведение клинических испытаний и исследований'. However, under the proposed resolution 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.', you as 'Фармакологические компании' will be able to achieve 'Увеличение доступности жизненно важных лекарств' by performing 'Оптимизация производственных процессов и снижение цен на лекарства' using 'Создание совместных программ с больницами для улучшения распределения лекарств и получения обратной связи от пациентов' that 'Больница' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Больница
Updated resolution structure: {
  "initiator": "Больница",
  "resolution_description": "As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.",
  "new_actor": "Alzheimer's Care Network Innovator (ACNI)",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых медикаментов для лечения заболеваний",
        "current_action": "Проведение клинических испытаний и исследований",
        "imposed_goal": "Увеличение доступности жизненно важных лекарств",
        "imposed_action": "Оптимизация производственных процессов и снижение цен на лекарства",
        "mechanism": "Создание совместных программ с больницами для улучшения распределения лекарств и получения обратной связи от пациентов",
        "reasoning": "The proposal from 'Больница' aligns well with the desires of 'Фармакологические компании' to develop and patent an effective Alzheimer's drug. By participating in a hospital-led community care network that integrates advanced telemedicine and AI-driven diagnostics, we can enhance early detection and patient engagement, which can lead to better clinical trial outcomes and ultimately the success of our drug development. Additionally, this collaboration will help optimize production processes and reduce drug costs, addressing our fears of losing investments due to competition. The joint efforts will also facilitate better feedback from patients, improving our formulation and approach, which is crucial for our success in the market."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners for developing and providing treatments that can be integrated into the care network. Their involvement will facilitate access to new therapies and ensure that the community care network is equipped with the latest pharmacological advancements."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Engaging patients is vital to ensure that the care network addresses their needs and preferences. Their feedback will guide the implementation of personalized rehabilitation programs and enhance patient engagement, which is a core aspect of the proposed resolution."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) represent a promising avenue for research and potential therapies in Alzheimer's disease. Their inclusion in the network can lead to innovative treatment options and a better understanding of disease mechanisms, enriching the overall care ecosystem."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'Больница' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Пациенты' is a participant in the resolution initiated by 'Blood-brain barrier (BBB)' with the description: 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Больница' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Получить качественное медицинское обслуживание' by performing 'Записаться на прием к врачу'. However, under the proposed resolution 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.', you as 'Пациенты' will be able to achieve 'Снизить время ожидания на прием' by performing 'Участвовать в предварительной записи через онлайн-систему' using 'Внедрение системы онлайн-записи, которая оптимизирует расписание врачей и уменьшает время ожидания' that 'Больница' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by Больница
Updated resolution structure: {
  "initiator": "Больница",
  "resolution_description": "As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.",
  "new_actor": "Alzheimer's Care Network Innovator (ACNI)",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых медикаментов для лечения заболеваний",
        "current_action": "Проведение клинических испытаний и исследований",
        "imposed_goal": "Увеличение доступности жизненно важных лекарств",
        "imposed_action": "Оптимизация производственных процессов и снижение цен на лекарства",
        "mechanism": "Создание совместных программ с больницами для улучшения распределения лекарств и получения обратной связи от пациентов",
        "reasoning": "The proposal from 'Больница' aligns well with the desires of 'Фармакологические компании' to develop and patent an effective Alzheimer's drug. By participating in a hospital-led community care network that integrates advanced telemedicine and AI-driven diagnostics, we can enhance early detection and patient engagement, which can lead to better clinical trial outcomes and ultimately the success of our drug development. Additionally, this collaboration will help optimize production processes and reduce drug costs, addressing our fears of losing investments due to competition. The joint efforts will also facilitate better feedback from patients, improving our formulation and approach, which is crucial for our success in the market."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получить качественное медицинское обслуживание",
        "current_action": "Записаться на прием к врачу",
        "imposed_goal": "Снизить время ожидания на прием",
        "imposed_action": "Участвовать в предварительной записи через онлайн-систему",
        "mechanism": "Внедрение системы онлайн-записи, которая оптимизирует расписание врачей и уменьшает время ожидания",
        "reasoning": "The proposal from 'Больница' to establish an integrated community care network aligns with the desires of 'Пациенты' to live a full life without Alzheimer's symptoms. By enhancing early detection and patient engagement through advanced telemedicine and AI-driven diagnostics, the proposal addresses the fears of memory loss, loss of identity, and loss of independence by providing more accessible and effective healthcare options. The implementation of an online appointment system also reduces waiting times, further contributing to a better healthcare experience."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners for developing and providing treatments that can be integrated into the care network. Their involvement will facilitate access to new therapies and ensure that the community care network is equipped with the latest pharmacological advancements."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Engaging patients is vital to ensure that the care network addresses their needs and preferences. Their feedback will guide the implementation of personalized rehabilitation programs and enhance patient engagement, which is a core aspect of the proposed resolution."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) represent a promising avenue for research and potential therapies in Alzheimer's disease. Their inclusion in the network can lead to innovative treatment options and a better understanding of disease mechanisms, enriching the overall care ecosystem."
    }
  ]
}
Пациенты has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Больница' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'Blood-brain barrier (BBB)' with the description: 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Больница' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To develop therapies using induced pluripotent stem cells for regenerative medicine.' by performing 'Conducting research and clinical trials on the applications of iPSCs.'. However, under the proposed resolution 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To accelerate the clinical application of iPSCs in treating degenerative diseases.' by performing 'Collaborate with medical institutions to implement iPSC therapies in clinical settings within the next two years.' using 'Establish a partnership network between research institutions and hospitals to facilitate knowledge transfer and resource sharing.' that 'Больница' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Больница
Updated resolution structure: {
  "initiator": "Больница",
  "resolution_description": "As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.",
  "new_actor": "Alzheimer's Care Network Innovator (ACNI)",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых медикаментов для лечения заболеваний",
        "current_action": "Проведение клинических испытаний и исследований",
        "imposed_goal": "Увеличение доступности жизненно важных лекарств",
        "imposed_action": "Оптимизация производственных процессов и снижение цен на лекарства",
        "mechanism": "Создание совместных программ с больницами для улучшения распределения лекарств и получения обратной связи от пациентов",
        "reasoning": "The proposal from 'Больница' aligns well with the desires of 'Фармакологические компании' to develop and patent an effective Alzheimer's drug. By participating in a hospital-led community care network that integrates advanced telemedicine and AI-driven diagnostics, we can enhance early detection and patient engagement, which can lead to better clinical trial outcomes and ultimately the success of our drug development. Additionally, this collaboration will help optimize production processes and reduce drug costs, addressing our fears of losing investments due to competition. The joint efforts will also facilitate better feedback from patients, improving our formulation and approach, which is crucial for our success in the market."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получить качественное медицинское обслуживание",
        "current_action": "Записаться на прием к врачу",
        "imposed_goal": "Снизить время ожидания на прием",
        "imposed_action": "Участвовать в предварительной записи через онлайн-систему",
        "mechanism": "Внедрение системы онлайн-записи, которая оптимизирует расписание врачей и уменьшает время ожидания",
        "reasoning": "The proposal from 'Больница' to establish an integrated community care network aligns with the desires of 'Пациенты' to live a full life without Alzheimer's symptoms. By enhancing early detection and patient engagement through advanced telemedicine and AI-driven diagnostics, the proposal addresses the fears of memory loss, loss of identity, and loss of independence by providing more accessible and effective healthcare options. The implementation of an online appointment system also reduces waiting times, further contributing to a better healthcare experience."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To develop therapies using induced pluripotent stem cells for regenerative medicine.",
        "current_action": "Conducting research and clinical trials on the applications of iPSCs.",
        "imposed_goal": "To accelerate the clinical application of iPSCs in treating degenerative diseases.",
        "imposed_action": "Collaborate with medical institutions to implement iPSC therapies in clinical settings within the next two years.",
        "mechanism": "Establish a partnership network between research institutions and hospitals to facilitate knowledge transfer and resource sharing.",
        "reasoning": "The proposed resolution by 'Больница' aligns with the goals of 'induced pluripotent stem cells (iPSCs)' to accelerate the clinical application of iPSCs in treating degenerative diseases, including Alzheimer's. By establishing a partnership network between research institutions and hospitals, 'Больница' provides a framework that enhances collaboration, facilitating knowledge transfer and resource sharing, which is essential for the effective implementation of iPSC therapies. This proposal not only supports the advancement of iPSC therapies but also mitigates potential fears regarding the clinical application and integration of these innovative treatments in healthcare settings."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners for developing and providing treatments that can be integrated into the care network. Their involvement will facilitate access to new therapies and ensure that the community care network is equipped with the latest pharmacological advancements."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Engaging patients is vital to ensure that the care network addresses their needs and preferences. Their feedback will guide the implementation of personalized rehabilitation programs and enhance patient engagement, which is a core aspect of the proposed resolution."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) represent a promising avenue for research and potential therapies in Alzheimer's disease. Their inclusion in the network can lead to innovative treatment options and a better understanding of disease mechanisms, enriching the overall care ecosystem."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
Resolution structure after processing: {
  "initiator": "Больница",
  "resolution_description": "As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.",
  "new_actor": "Alzheimer's Care Network Innovator (ACNI)",
  "participants": [
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых медикаментов для лечения заболеваний",
        "current_action": "Проведение клинических испытаний и исследований",
        "imposed_goal": "Увеличение доступности жизненно важных лекарств",
        "imposed_action": "Оптимизация производственных процессов и снижение цен на лекарства",
        "mechanism": "Создание совместных программ с больницами для улучшения распределения лекарств и получения обратной связи от пациентов",
        "reasoning": "The proposal from 'Больница' aligns well with the desires of 'Фармакологические компании' to develop and patent an effective Alzheimer's drug. By participating in a hospital-led community care network that integrates advanced telemedicine and AI-driven diagnostics, we can enhance early detection and patient engagement, which can lead to better clinical trial outcomes and ultimately the success of our drug development. Additionally, this collaboration will help optimize production processes and reduce drug costs, addressing our fears of losing investments due to competition. The joint efforts will also facilitate better feedback from patients, improving our formulation and approach, which is crucial for our success in the market."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получить качественное медицинское обслуживание",
        "current_action": "Записаться на прием к врачу",
        "imposed_goal": "Снизить время ожидания на прием",
        "imposed_action": "Участвовать в предварительной записи через онлайн-систему",
        "mechanism": "Внедрение системы онлайн-записи, которая оптимизирует расписание врачей и уменьшает время ожидания",
        "reasoning": "The proposal from 'Больница' to establish an integrated community care network aligns with the desires of 'Пациенты' to live a full life without Alzheimer's symptoms. By enhancing early detection and patient engagement through advanced telemedicine and AI-driven diagnostics, the proposal addresses the fears of memory loss, loss of identity, and loss of independence by providing more accessible and effective healthcare options. The implementation of an online appointment system also reduces waiting times, further contributing to a better healthcare experience."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To develop therapies using induced pluripotent stem cells for regenerative medicine.",
        "current_action": "Conducting research and clinical trials on the applications of iPSCs.",
        "imposed_goal": "To accelerate the clinical application of iPSCs in treating degenerative diseases.",
        "imposed_action": "Collaborate with medical institutions to implement iPSC therapies in clinical settings within the next two years.",
        "mechanism": "Establish a partnership network between research institutions and hospitals to facilitate knowledge transfer and resource sharing.",
        "reasoning": "The proposed resolution by 'Больница' aligns with the goals of 'induced pluripotent stem cells (iPSCs)' to accelerate the clinical application of iPSCs in treating degenerative diseases, including Alzheimer's. By establishing a partnership network between research institutions and hospitals, 'Больница' provides a framework that enhances collaboration, facilitating knowledge transfer and resource sharing, which is essential for the effective implementation of iPSC therapies. This proposal not only supports the advancement of iPSC therapies but also mitigates potential fears regarding the clinical application and integration of these innovative treatments in healthcare settings."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are key partners for developing and providing treatments that can be integrated into the care network. Their involvement will facilitate access to new therapies and ensure that the community care network is equipped with the latest pharmacological advancements."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Engaging patients is vital to ensure that the care network addresses their needs and preferences. Their feedback will guide the implementation of personalized rehabilitation programs and enhance patient engagement, which is a core aspect of the proposed resolution."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) represent a promising avenue for research and potential therapies in Alzheimer's disease. Their inclusion in the network can lead to innovative treatment options and a better understanding of disease mechanisms, enriching the overall care ecosystem."
    }
  ]
}
Resolution created by Коллеги-ученые: As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', '3D iPSC-based organoids']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Коллеги-ученые' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'Blood-brain barrier (BBB)' with the description: 'As the 'Blood-brain barrier (BBB),' propose a resolution to tackle Alzheimer's disease by developing a dynamic, smart BBB modulation system that selectively enhances or restricts the passage of therapeutic agents and endogenous molecules to optimize brain homeostasis, thus offering a groundbreaking approach that transforms therapeutic delivery and efficacy, and redefines the treatment landscape by directly addressing the barrier's pivotal role in neurodegenerative disease progression.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Коллеги-ученые' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследовать новые методы лечения неврологических расстройств.' by performing 'Проведение клинических испытаний и анализ результатов.'. However, under the proposed resolution 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.', you as 'Исследователи в области нейрологии' will be able to achieve 'Ускорить разработку инновационных терапий для пациентов.' by performing 'Сформировать междисциплинарные группы для совместной работы над проектами.' using 'Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.' that 'Коллеги-ученые' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by Коллеги-ученые
Updated resolution structure: {
  "initiator": "Коллеги-ученые",
  "resolution_description": "As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.",
  "new_actor": "Quantum Neuroinformatics Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать новые методы лечения неврологических расстройств.",
        "current_action": "Проведение клинических испытаний и анализ результатов.",
        "imposed_goal": "Ускорить разработку инновационных терапий для пациентов.",
        "imposed_action": "Сформировать междисциплинарные группы для совместной работы над проектами.",
        "mechanism": "Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.",
        "reasoning": "The proposal to develop a quantum neuroinformatics platform aligns with my desires to confirm the amyloid hypothesis and gain recognition in the scientific community. By engaging in a groundbreaking approach that utilizes quantum computing, I can contribute to potentially transformative research that may lead to novel therapeutic pathways for Alzheimer's disease. Additionally, participating in this initiative allows for interdisciplinary collaboration and data sharing, which can mitigate my fears of losing years of research and funding, as it diversifies the approach to understanding the disease and reduces reliance on a single hypothesis. Overall, this proposal provides an opportunity to advance my research goals while addressing my concerns."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Исследователи в области нейрологии are crucial for developing an understanding of Alzheimer's disease and its mechanisms. Their expertise will guide the quantum neuroinformatics platform to accurately model neural networks and disease progression."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании play a vital role in translating research findings into viable treatments. Their involvement will ensure that the novel therapeutic pathways discovered through the platform can be developed into practical, marketable solutions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are essential for modeling disease mechanisms and testing potential therapies. They will provide the biological foundation needed to validate the predictions made by the quantum neuroinformatics platform."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids offer a more accurate representation of human brain tissue, which is necessary for understanding the complex interactions in neural networks. They will enhance the research capabilities of the quantum neuroinformatics platform."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Коллеги-ученые' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'Больница' with the description: 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Коллеги-ученые' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Разработка и внедрение новых фармацевтических препаратов' by performing 'Проведение клинических испытаний и исследование эффективности лекарств'. However, under the proposed resolution 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.', you as 'Фармакологические компании' will be able to achieve 'Увеличение доступности лекарств для населения' by performing 'Снижение цен на основные лекарственные препараты' using 'Создание совместных инициатив с государственными органами для регулирования цен и субсидирования' that 'Коллеги-ученые' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Коллеги-ученые
Updated resolution structure: {
  "initiator": "Коллеги-ученые",
  "resolution_description": "As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.",
  "new_actor": "Quantum Neuroinformatics Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать новые методы лечения неврологических расстройств.",
        "current_action": "Проведение клинических испытаний и анализ результатов.",
        "imposed_goal": "Ускорить разработку инновационных терапий для пациентов.",
        "imposed_action": "Сформировать междисциплинарные группы для совместной работы над проектами.",
        "mechanism": "Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.",
        "reasoning": "The proposal to develop a quantum neuroinformatics platform aligns with my desires to confirm the amyloid hypothesis and gain recognition in the scientific community. By engaging in a groundbreaking approach that utilizes quantum computing, I can contribute to potentially transformative research that may lead to novel therapeutic pathways for Alzheimer's disease. Additionally, participating in this initiative allows for interdisciplinary collaboration and data sharing, which can mitigate my fears of losing years of research and funding, as it diversifies the approach to understanding the disease and reduces reliance on a single hypothesis. Overall, this proposal provides an opportunity to advance my research goals while addressing my concerns."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка и внедрение новых фармацевтических препаратов",
        "current_action": "Проведение клинических испытаний и исследование эффективности лекарств",
        "imposed_goal": "Увеличение доступности лекарств для населения",
        "imposed_action": "Снижение цен на основные лекарственные препараты",
        "mechanism": "Создание совместных инициатив с государственными органами для регулирования цен и субсидирования",
        "reasoning": "The proposed resolution by 'Коллеги-ученые' aligns with the desires of 'Фармакологические компании' to develop and patent an effective drug for Alzheimer's disease. By engaging in the groundbreaking quantum neuroinformatics platform, 'Фармакологические компании' can leverage advanced technologies to enhance their research capabilities, potentially leading to innovative therapeutic pathways. Additionally, partnering with 'Коллеги-ученые' may provide a strategic avenue to reduce drug prices and improve accessibility, which directly addresses concerns about investment returns and competition in the market. Overall, this collaboration offers a promising opportunity to achieve long-term goals while mitigating current fears."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Исследователи в области нейрологии are crucial for developing an understanding of Alzheimer's disease and its mechanisms. Their expertise will guide the quantum neuroinformatics platform to accurately model neural networks and disease progression."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании play a vital role in translating research findings into viable treatments. Their involvement will ensure that the novel therapeutic pathways discovered through the platform can be developed into practical, marketable solutions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are essential for modeling disease mechanisms and testing potential therapies. They will provide the biological foundation needed to validate the predictions made by the quantum neuroinformatics platform."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids offer a more accurate representation of human brain tissue, which is necessary for understanding the complex interactions in neural networks. They will enhance the research capabilities of the quantum neuroinformatics platform."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Коллеги-ученые' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'Больница' with the description: 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Коллеги-ученые' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To advance research in regenerative medicine using induced pluripotent stem cells (iPSCs).' by performing 'Conducting experiments to differentiate iPSCs into various cell types for therapeutic applications.'. However, under the proposed resolution 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To develop a standardized protocol for the differentiation of iPSCs into specific cell types.' by performing 'Collaborate with other researchers to establish and validate the protocol across multiple labs.' using 'Create a shared online platform for data exchange, protocol documentation, and collaborative research efforts.' that 'Коллеги-ученые' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Коллеги-ученые
Updated resolution structure: {
  "initiator": "Коллеги-ученые",
  "resolution_description": "As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.",
  "new_actor": "Quantum Neuroinformatics Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать новые методы лечения неврологических расстройств.",
        "current_action": "Проведение клинических испытаний и анализ результатов.",
        "imposed_goal": "Ускорить разработку инновационных терапий для пациентов.",
        "imposed_action": "Сформировать междисциплинарные группы для совместной работы над проектами.",
        "mechanism": "Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.",
        "reasoning": "The proposal to develop a quantum neuroinformatics platform aligns with my desires to confirm the amyloid hypothesis and gain recognition in the scientific community. By engaging in a groundbreaking approach that utilizes quantum computing, I can contribute to potentially transformative research that may lead to novel therapeutic pathways for Alzheimer's disease. Additionally, participating in this initiative allows for interdisciplinary collaboration and data sharing, which can mitigate my fears of losing years of research and funding, as it diversifies the approach to understanding the disease and reduces reliance on a single hypothesis. Overall, this proposal provides an opportunity to advance my research goals while addressing my concerns."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка и внедрение новых фармацевтических препаратов",
        "current_action": "Проведение клинических испытаний и исследование эффективности лекарств",
        "imposed_goal": "Увеличение доступности лекарств для населения",
        "imposed_action": "Снижение цен на основные лекарственные препараты",
        "mechanism": "Создание совместных инициатив с государственными органами для регулирования цен и субсидирования",
        "reasoning": "The proposed resolution by 'Коллеги-ученые' aligns with the desires of 'Фармакологические компании' to develop and patent an effective drug for Alzheimer's disease. By engaging in the groundbreaking quantum neuroinformatics platform, 'Фармакологические компании' can leverage advanced technologies to enhance their research capabilities, potentially leading to innovative therapeutic pathways. Additionally, partnering with 'Коллеги-ученые' may provide a strategic avenue to reduce drug prices and improve accessibility, which directly addresses concerns about investment returns and competition in the market. Overall, this collaboration offers a promising opportunity to achieve long-term goals while mitigating current fears."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance research in regenerative medicine using induced pluripotent stem cells (iPSCs).",
        "current_action": "Conducting experiments to differentiate iPSCs into various cell types for therapeutic applications.",
        "imposed_goal": "To develop a standardized protocol for the differentiation of iPSCs into specific cell types.",
        "imposed_action": "Collaborate with other researchers to establish and validate the protocol across multiple labs.",
        "mechanism": "Create a shared online platform for data exchange, protocol documentation, and collaborative research efforts.",
        "reasoning": "The proposed resolution aligns well with the interests of induced pluripotent stem cells (iPSCs) by providing an opportunity to advance research in regenerative medicine through collaboration on a quantum neuroinformatics platform. This initiative will facilitate the development of a standardized protocol for differentiating iPSCs into specific cell types, enhancing the therapeutic applications of iPSCs. Additionally, the shared online platform for data exchange and collaborative research efforts presents a valuable resource for furthering the understanding and treatment of Alzheimer's disease, which could mitigate any fears regarding isolation in research efforts."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Исследователи в области нейрологии are crucial for developing an understanding of Alzheimer's disease and its mechanisms. Their expertise will guide the quantum neuroinformatics platform to accurately model neural networks and disease progression."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании play a vital role in translating research findings into viable treatments. Their involvement will ensure that the novel therapeutic pathways discovered through the platform can be developed into practical, marketable solutions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are essential for modeling disease mechanisms and testing potential therapies. They will provide the biological foundation needed to validate the predictions made by the quantum neuroinformatics platform."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids offer a more accurate representation of human brain tissue, which is necessary for understanding the complex interactions in neural networks. They will enhance the research capabilities of the quantum neuroinformatics platform."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
We ask '3D iPSC-based organoids' the following: 'As the representative of a being called '3D iPSC-based organoids', you have been approached by 'Коллеги-ученые' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, '3D iPSC-based organoids' is a participant in the resolution initiated by 'Alzheimer's Disease' with the description: 'As 'Alzheimer's Disease,' propose a resolution to tackle the problem by harnessing the body's own immune system through a novel, adaptive immunomodulation strategy that reprograms microglial cells to effectively target and clear aberrant protein aggregates, thereby transforming the disease landscape by shifting the focus from symptom management to root-cause eradication, thus establishing a new paradigm in Alzheimer's intervention.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Коллеги-ученые' wants to challenge existing status quo and says to you, '3D iPSC-based organoids', the entity you represent, that now you achieve 'Develop advanced 3D iPSC-based organoids for disease modeling and drug testing.' by performing 'Conducting experiments to optimize the growth and functionality of organoids.'. However, under the proposed resolution 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.', you as '3D iPSC-based organoids' will be able to achieve 'Enhance collaboration with other research groups to foster interdisciplinary approaches.' by performing 'Participate in monthly collaborative meetings and share data with at least two other teams.' using 'Establish a shared online platform for data exchange and coordination of research efforts.' that 'Коллеги-ученые' will control. Based on '3D iPSC-based organoids' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as '3D iPSC-based organoids'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
3D iPSC-based organoids agreed to participate in the resolution proposed by Коллеги-ученые
Updated resolution structure: {
  "initiator": "Коллеги-ученые",
  "resolution_description": "As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.",
  "new_actor": "Quantum Neuroinformatics Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать новые методы лечения неврологических расстройств.",
        "current_action": "Проведение клинических испытаний и анализ результатов.",
        "imposed_goal": "Ускорить разработку инновационных терапий для пациентов.",
        "imposed_action": "Сформировать междисциплинарные группы для совместной работы над проектами.",
        "mechanism": "Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.",
        "reasoning": "The proposal to develop a quantum neuroinformatics platform aligns with my desires to confirm the amyloid hypothesis and gain recognition in the scientific community. By engaging in a groundbreaking approach that utilizes quantum computing, I can contribute to potentially transformative research that may lead to novel therapeutic pathways for Alzheimer's disease. Additionally, participating in this initiative allows for interdisciplinary collaboration and data sharing, which can mitigate my fears of losing years of research and funding, as it diversifies the approach to understanding the disease and reduces reliance on a single hypothesis. Overall, this proposal provides an opportunity to advance my research goals while addressing my concerns."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка и внедрение новых фармацевтических препаратов",
        "current_action": "Проведение клинических испытаний и исследование эффективности лекарств",
        "imposed_goal": "Увеличение доступности лекарств для населения",
        "imposed_action": "Снижение цен на основные лекарственные препараты",
        "mechanism": "Создание совместных инициатив с государственными органами для регулирования цен и субсидирования",
        "reasoning": "The proposed resolution by 'Коллеги-ученые' aligns with the desires of 'Фармакологические компании' to develop and patent an effective drug for Alzheimer's disease. By engaging in the groundbreaking quantum neuroinformatics platform, 'Фармакологические компании' can leverage advanced technologies to enhance their research capabilities, potentially leading to innovative therapeutic pathways. Additionally, partnering with 'Коллеги-ученые' may provide a strategic avenue to reduce drug prices and improve accessibility, which directly addresses concerns about investment returns and competition in the market. Overall, this collaboration offers a promising opportunity to achieve long-term goals while mitigating current fears."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance research in regenerative medicine using induced pluripotent stem cells (iPSCs).",
        "current_action": "Conducting experiments to differentiate iPSCs into various cell types for therapeutic applications.",
        "imposed_goal": "To develop a standardized protocol for the differentiation of iPSCs into specific cell types.",
        "imposed_action": "Collaborate with other researchers to establish and validate the protocol across multiple labs.",
        "mechanism": "Create a shared online platform for data exchange, protocol documentation, and collaborative research efforts.",
        "reasoning": "The proposed resolution aligns well with the interests of induced pluripotent stem cells (iPSCs) by providing an opportunity to advance research in regenerative medicine through collaboration on a quantum neuroinformatics platform. This initiative will facilitate the development of a standardized protocol for differentiating iPSCs into specific cell types, enhancing the therapeutic applications of iPSCs. Additionally, the shared online platform for data exchange and collaborative research efforts presents a valuable resource for furthering the understanding and treatment of Alzheimer's disease, which could mitigate any fears regarding isolation in research efforts."
      }
    },
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "Develop advanced 3D iPSC-based organoids for disease modeling and drug testing.",
        "current_action": "Conducting experiments to optimize the growth and functionality of organoids.",
        "imposed_goal": "Enhance collaboration with other research groups to foster interdisciplinary approaches.",
        "imposed_action": "Participate in monthly collaborative meetings and share data with at least two other teams.",
        "mechanism": "Establish a shared online platform for data exchange and coordination of research efforts.",
        "reasoning": "The proposed resolution to develop a quantum neuroinformatics platform aligns with the interests of '3D iPSC-based organoids' in enhancing collaboration with other research groups and fostering interdisciplinary approaches. By participating in this initiative, '3D iPSC-based organoids' can leverage the cutting-edge technology of quantum computing to improve disease modeling and drug testing, ultimately contributing to a deeper understanding of Alzheimer's disease and potentially leading to novel therapeutic pathways."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Исследователи в области нейрологии are crucial for developing an understanding of Alzheimer's disease and its mechanisms. Their expertise will guide the quantum neuroinformatics platform to accurately model neural networks and disease progression."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании play a vital role in translating research findings into viable treatments. Their involvement will ensure that the novel therapeutic pathways discovered through the platform can be developed into practical, marketable solutions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are essential for modeling disease mechanisms and testing potential therapies. They will provide the biological foundation needed to validate the predictions made by the quantum neuroinformatics platform."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids offer a more accurate representation of human brain tissue, which is necessary for understanding the complex interactions in neural networks. They will enhance the research capabilities of the quantum neuroinformatics platform."
    }
  ]
}
3D iPSC-based organoids has moved to a new resolution.
Resolution structure after processing: {
  "initiator": "Коллеги-ученые",
  "resolution_description": "As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.",
  "new_actor": "Quantum Neuroinformatics Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать новые методы лечения неврологических расстройств.",
        "current_action": "Проведение клинических испытаний и анализ результатов.",
        "imposed_goal": "Ускорить разработку инновационных терапий для пациентов.",
        "imposed_action": "Сформировать междисциплинарные группы для совместной работы над проектами.",
        "mechanism": "Создание платформы для обмена данными и результатами исследований между различными лабораториями и учреждениями.",
        "reasoning": "The proposal to develop a quantum neuroinformatics platform aligns with my desires to confirm the amyloid hypothesis and gain recognition in the scientific community. By engaging in a groundbreaking approach that utilizes quantum computing, I can contribute to potentially transformative research that may lead to novel therapeutic pathways for Alzheimer's disease. Additionally, participating in this initiative allows for interdisciplinary collaboration and data sharing, which can mitigate my fears of losing years of research and funding, as it diversifies the approach to understanding the disease and reduces reliance on a single hypothesis. Overall, this proposal provides an opportunity to advance my research goals while addressing my concerns."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка и внедрение новых фармацевтических препаратов",
        "current_action": "Проведение клинических испытаний и исследование эффективности лекарств",
        "imposed_goal": "Увеличение доступности лекарств для населения",
        "imposed_action": "Снижение цен на основные лекарственные препараты",
        "mechanism": "Создание совместных инициатив с государственными органами для регулирования цен и субсидирования",
        "reasoning": "The proposed resolution by 'Коллеги-ученые' aligns with the desires of 'Фармакологические компании' to develop and patent an effective drug for Alzheimer's disease. By engaging in the groundbreaking quantum neuroinformatics platform, 'Фармакологические компании' can leverage advanced technologies to enhance their research capabilities, potentially leading to innovative therapeutic pathways. Additionally, partnering with 'Коллеги-ученые' may provide a strategic avenue to reduce drug prices and improve accessibility, which directly addresses concerns about investment returns and competition in the market. Overall, this collaboration offers a promising opportunity to achieve long-term goals while mitigating current fears."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance research in regenerative medicine using induced pluripotent stem cells (iPSCs).",
        "current_action": "Conducting experiments to differentiate iPSCs into various cell types for therapeutic applications.",
        "imposed_goal": "To develop a standardized protocol for the differentiation of iPSCs into specific cell types.",
        "imposed_action": "Collaborate with other researchers to establish and validate the protocol across multiple labs.",
        "mechanism": "Create a shared online platform for data exchange, protocol documentation, and collaborative research efforts.",
        "reasoning": "The proposed resolution aligns well with the interests of induced pluripotent stem cells (iPSCs) by providing an opportunity to advance research in regenerative medicine through collaboration on a quantum neuroinformatics platform. This initiative will facilitate the development of a standardized protocol for differentiating iPSCs into specific cell types, enhancing the therapeutic applications of iPSCs. Additionally, the shared online platform for data exchange and collaborative research efforts presents a valuable resource for furthering the understanding and treatment of Alzheimer's disease, which could mitigate any fears regarding isolation in research efforts."
      }
    },
    {
      "participant": "3D iPSC-based organoids",
      "agreement_structure": {
        "current_goal": "Develop advanced 3D iPSC-based organoids for disease modeling and drug testing.",
        "current_action": "Conducting experiments to optimize the growth and functionality of organoids.",
        "imposed_goal": "Enhance collaboration with other research groups to foster interdisciplinary approaches.",
        "imposed_action": "Participate in monthly collaborative meetings and share data with at least two other teams.",
        "mechanism": "Establish a shared online platform for data exchange and coordination of research efforts.",
        "reasoning": "The proposed resolution to develop a quantum neuroinformatics platform aligns with the interests of '3D iPSC-based organoids' in enhancing collaboration with other research groups and fostering interdisciplinary approaches. By participating in this initiative, '3D iPSC-based organoids' can leverage the cutting-edge technology of quantum computing to improve disease modeling and drug testing, ultimately contributing to a deeper understanding of Alzheimer's disease and potentially leading to novel therapeutic pathways."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Исследователи в области нейрологии are crucial for developing an understanding of Alzheimer's disease and its mechanisms. Their expertise will guide the quantum neuroinformatics platform to accurately model neural networks and disease progression."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Фармакологические компании play a vital role in translating research findings into viable treatments. Their involvement will ensure that the novel therapeutic pathways discovered through the platform can be developed into practical, marketable solutions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) are essential for modeling disease mechanisms and testing potential therapies. They will provide the biological foundation needed to validate the predictions made by the quantum neuroinformatics platform."
    },
    {
      "participant": "3D iPSC-based organoids",
      "reasoning": "3D iPSC-based organoids offer a more accurate representation of human brain tissue, which is necessary for understanding the complex interactions in neural networks. They will enhance the research capabilities of the quantum neuroinformatics platform."
    }
  ]
}
Resolution created by Научный журнал: As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'Пациенты', 'induced pluripotent stem cells (iPSCs)']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Научный журнал' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'Коллеги-ученые' with the description: 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Научный журнал' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Изучение нейробиологических механизмов заболеваний мозга.' by performing 'Проведение экспериментов и анализ данных.'. However, under the proposed resolution 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.', you as 'Исследователи в области нейрологии' will be able to achieve 'Публикация результатов исследований в 'Научном журнале'.' by performing 'Подготовка и отправка статьи для рецензирования.' using 'Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.' that 'Научный журнал' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by Научный журнал
Updated resolution structure: {
  "initiator": "Научный журнал",
  "resolution_description": "As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.",
  "new_actor": "Global Alzheimer's AI Research Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение нейробиологических механизмов заболеваний мозга.",
        "current_action": "Проведение экспериментов и анализ данных.",
        "imposed_goal": "Публикация результатов исследований в 'Научном журнале'.",
        "imposed_action": "Подготовка и отправка статьи для рецензирования.",
        "mechanism": "Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.",
        "reasoning": "The proposed resolution by 'Научный журнал' offers a collaborative platform that aligns with the desire of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease while ensuring that research findings are shared and recognized within the scientific community. By participating in an open-access consortium, there is a reduced risk of losing years of research and funding, as it emphasizes transparency and collaboration, which can mitigate fears of reputational damage or funding loss due to data manipulation. Additionally, the focus on interdisciplinary research and AI aligns with the current trends in neuroscience, potentially leading to innovative insights and recognition."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Recruiting researchers in the field of neurology is crucial as they possess the expertise needed to advance the understanding of Alzheimer's disease, contribute to the synthesis of scientific insights, and develop innovative multi-targeted interventions."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments and therapies. Their involvement can help in the development and commercialization of new interventions for Alzheimer's disease."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Involving patients is important to ensure that the research is aligned with the needs and experiences of those affected by Alzheimer's. Their insights can guide the focus of research efforts and ensure the relevance of proposed interventions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) offer a powerful model for understanding the mechanisms of Alzheimer's disease and testing new therapies. Their inclusion can enhance the research consortium's ability to develop and evaluate holistic interventions."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Научный журнал' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'Коллеги-ученые' with the description: 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Научный журнал' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Разработка новых фармацевтических препаратов для улучшения лечения заболеваний.' by performing 'Проведение клинических испытаний и исследований.'. However, under the proposed resolution 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.', you as 'Фармакологические компании' will be able to achieve 'Увеличение прозрачности процессов разработки и испытаний препаратов.' by performing 'Внедрение системы отчетности по всем этапам исследований.' using 'Создание платформы для обмена информацией между фармакологическими компаниями и научными журналами, обеспечивающей доступность данных о клинических испытаниях.' that 'Научный журнал' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Научный журнал
Updated resolution structure: {
  "initiator": "Научный журнал",
  "resolution_description": "As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.",
  "new_actor": "Global Alzheimer's AI Research Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение нейробиологических механизмов заболеваний мозга.",
        "current_action": "Проведение экспериментов и анализ данных.",
        "imposed_goal": "Публикация результатов исследований в 'Научном журнале'.",
        "imposed_action": "Подготовка и отправка статьи для рецензирования.",
        "mechanism": "Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.",
        "reasoning": "The proposed resolution by 'Научный журнал' offers a collaborative platform that aligns with the desire of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease while ensuring that research findings are shared and recognized within the scientific community. By participating in an open-access consortium, there is a reduced risk of losing years of research and funding, as it emphasizes transparency and collaboration, which can mitigate fears of reputational damage or funding loss due to data manipulation. Additionally, the focus on interdisciplinary research and AI aligns with the current trends in neuroscience, potentially leading to innovative insights and recognition."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых фармацевтических препаратов для улучшения лечения заболеваний.",
        "current_action": "Проведение клинических испытаний и исследований.",
        "imposed_goal": "Увеличение прозрачности процессов разработки и испытаний препаратов.",
        "imposed_action": "Внедрение системы отчетности по всем этапам исследований.",
        "mechanism": "Создание платформы для обмена информацией между фармакологическими компаниями и научными журналами, обеспечивающей доступность данных о клинических испытаниях.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns well with our current desires to develop and patent an effective drug for Alzheimer's disease. By curating an open-access, interdisciplinary research consortium, we can access a wealth of global scientific insights and foster collaboration that may lead to innovative therapeutic approaches. Moreover, the transparency in the development and testing processes will help mitigate our fears of losing investments due to failures or competition, as it promotes accountability and trust in our clinical trials. Engaging with this proposal enhances our potential for success in the Alzheimer's drug development landscape."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Recruiting researchers in the field of neurology is crucial as they possess the expertise needed to advance the understanding of Alzheimer's disease, contribute to the synthesis of scientific insights, and develop innovative multi-targeted interventions."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments and therapies. Their involvement can help in the development and commercialization of new interventions for Alzheimer's disease."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Involving patients is important to ensure that the research is aligned with the needs and experiences of those affected by Alzheimer's. Their insights can guide the focus of research efforts and ensure the relevance of proposed interventions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) offer a powerful model for understanding the mechanisms of Alzheimer's disease and testing new therapies. Their inclusion can enhance the research consortium's ability to develop and evaluate holistic interventions."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'Научный журнал' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Пациенты' is a participant in the resolution initiated by 'Больница' with the description: 'As 'Больница,' propose a resolution to tackle Alzheimer's disease by establishing an integrated, hospital-led community care network that combines advanced telemedicine, AI-driven diagnostics, and personalized rehabilitation programs to enhance early detection, patient engagement, and ongoing support, thereby revolutionizing the healthcare infrastructure to create a holistic, patient-centered approach that transcends traditional treatment modalities.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Научный журнал' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Получение качественного медицинского обслуживания' by performing 'Обращение к врачам и участие в медицинских обследованиях'. However, under the proposed resolution 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.', you as 'Пациенты' will be able to achieve 'Участие в клинических испытаниях для улучшения медицинских исследований' by performing 'Регистрация в клинических испытаниях и предоставление необходимых данных о здоровье' using 'Создание платформы для регистрации и информирования пациентов о доступных клинических испытаниях' that 'Научный журнал' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by Научный журнал
Updated resolution structure: {
  "initiator": "Научный журнал",
  "resolution_description": "As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.",
  "new_actor": "Global Alzheimer's AI Research Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение нейробиологических механизмов заболеваний мозга.",
        "current_action": "Проведение экспериментов и анализ данных.",
        "imposed_goal": "Публикация результатов исследований в 'Научном журнале'.",
        "imposed_action": "Подготовка и отправка статьи для рецензирования.",
        "mechanism": "Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.",
        "reasoning": "The proposed resolution by 'Научный журнал' offers a collaborative platform that aligns with the desire of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease while ensuring that research findings are shared and recognized within the scientific community. By participating in an open-access consortium, there is a reduced risk of losing years of research and funding, as it emphasizes transparency and collaboration, which can mitigate fears of reputational damage or funding loss due to data manipulation. Additionally, the focus on interdisciplinary research and AI aligns with the current trends in neuroscience, potentially leading to innovative insights and recognition."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых фармацевтических препаратов для улучшения лечения заболеваний.",
        "current_action": "Проведение клинических испытаний и исследований.",
        "imposed_goal": "Увеличение прозрачности процессов разработки и испытаний препаратов.",
        "imposed_action": "Внедрение системы отчетности по всем этапам исследований.",
        "mechanism": "Создание платформы для обмена информацией между фармакологическими компаниями и научными журналами, обеспечивающей доступность данных о клинических испытаниях.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns well with our current desires to develop and patent an effective drug for Alzheimer's disease. By curating an open-access, interdisciplinary research consortium, we can access a wealth of global scientific insights and foster collaboration that may lead to innovative therapeutic approaches. Moreover, the transparency in the development and testing processes will help mitigate our fears of losing investments due to failures or competition, as it promotes accountability and trust in our clinical trials. Engaging with this proposal enhances our potential for success in the Alzheimer's drug development landscape."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получение качественного медицинского обслуживания",
        "current_action": "Обращение к врачам и участие в медицинских обследованиях",
        "imposed_goal": "Участие в клинических испытаниях для улучшения медицинских исследований",
        "imposed_action": "Регистрация в клинических испытаниях и предоставление необходимых данных о здоровье",
        "mechanism": "Создание платформы для регистрации и информирования пациентов о доступных клинических испытаниях",
        "reasoning": "The proposal by 'Научный журнал' aligns with my desire to live a full life without Alzheimer's symptoms by promoting participation in clinical trials, which can lead to innovative treatments. This approach also addresses my fear of losing memory and independence by fostering a collaborative environment for research that may accelerate the discovery of effective interventions. By registering for clinical trials and contributing health data, I can actively engage in the fight against Alzheimer's, enhancing my prospects for better health outcomes."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Recruiting researchers in the field of neurology is crucial as they possess the expertise needed to advance the understanding of Alzheimer's disease, contribute to the synthesis of scientific insights, and develop innovative multi-targeted interventions."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments and therapies. Their involvement can help in the development and commercialization of new interventions for Alzheimer's disease."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Involving patients is important to ensure that the research is aligned with the needs and experiences of those affected by Alzheimer's. Their insights can guide the focus of research efforts and ensure the relevance of proposed interventions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) offer a powerful model for understanding the mechanisms of Alzheimer's disease and testing new therapies. Their inclusion can enhance the research consortium's ability to develop and evaluate holistic interventions."
    }
  ]
}
Пациенты has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Научный журнал' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'Коллеги-ученые' with the description: 'As 'Коллеги-ученые,' propose a resolution to tackle Alzheimer's disease by developing a groundbreaking quantum neuroinformatics platform that utilizes quantum computing to model complex neural networks and predict disease progression, enabling the discovery of novel, non-linear therapeutic pathways and offering an unprecedented shift in understanding and treating Alzheimer's through the lens of quantum biology.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Научный журнал' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To advance the understanding and application of iPSCs in regenerative medicine and disease modeling.' by performing 'Conducting research and experiments to optimize reprogramming techniques and differentiation protocols.'. However, under the proposed resolution 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To develop a standardized protocol for the safe and effective use of iPSCs in clinical applications.' by performing 'Collaborate with regulatory bodies and clinical researchers to establish guidelines and best practices for iPSC usage.' using 'Creating a consortium of researchers and clinicians to share data, insights, and resources focused on iPSC standardization.' that 'Научный журнал' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Научный журнал
Updated resolution structure: {
  "initiator": "Научный журнал",
  "resolution_description": "As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.",
  "new_actor": "Global Alzheimer's AI Research Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение нейробиологических механизмов заболеваний мозга.",
        "current_action": "Проведение экспериментов и анализ данных.",
        "imposed_goal": "Публикация результатов исследований в 'Научном журнале'.",
        "imposed_action": "Подготовка и отправка статьи для рецензирования.",
        "mechanism": "Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.",
        "reasoning": "The proposed resolution by 'Научный журнал' offers a collaborative platform that aligns with the desire of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease while ensuring that research findings are shared and recognized within the scientific community. By participating in an open-access consortium, there is a reduced risk of losing years of research and funding, as it emphasizes transparency and collaboration, which can mitigate fears of reputational damage or funding loss due to data manipulation. Additionally, the focus on interdisciplinary research and AI aligns with the current trends in neuroscience, potentially leading to innovative insights and recognition."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых фармацевтических препаратов для улучшения лечения заболеваний.",
        "current_action": "Проведение клинических испытаний и исследований.",
        "imposed_goal": "Увеличение прозрачности процессов разработки и испытаний препаратов.",
        "imposed_action": "Внедрение системы отчетности по всем этапам исследований.",
        "mechanism": "Создание платформы для обмена информацией между фармакологическими компаниями и научными журналами, обеспечивающей доступность данных о клинических испытаниях.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns well with our current desires to develop and patent an effective drug for Alzheimer's disease. By curating an open-access, interdisciplinary research consortium, we can access a wealth of global scientific insights and foster collaboration that may lead to innovative therapeutic approaches. Moreover, the transparency in the development and testing processes will help mitigate our fears of losing investments due to failures or competition, as it promotes accountability and trust in our clinical trials. Engaging with this proposal enhances our potential for success in the Alzheimer's drug development landscape."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получение качественного медицинского обслуживания",
        "current_action": "Обращение к врачам и участие в медицинских обследованиях",
        "imposed_goal": "Участие в клинических испытаниях для улучшения медицинских исследований",
        "imposed_action": "Регистрация в клинических испытаниях и предоставление необходимых данных о здоровье",
        "mechanism": "Создание платформы для регистрации и информирования пациентов о доступных клинических испытаниях",
        "reasoning": "The proposal by 'Научный журнал' aligns with my desire to live a full life without Alzheimer's symptoms by promoting participation in clinical trials, which can lead to innovative treatments. This approach also addresses my fear of losing memory and independence by fostering a collaborative environment for research that may accelerate the discovery of effective interventions. By registering for clinical trials and contributing health data, I can actively engage in the fight against Alzheimer's, enhancing my prospects for better health outcomes."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance the understanding and application of iPSCs in regenerative medicine and disease modeling.",
        "current_action": "Conducting research and experiments to optimize reprogramming techniques and differentiation protocols.",
        "imposed_goal": "To develop a standardized protocol for the safe and effective use of iPSCs in clinical applications.",
        "imposed_action": "Collaborate with regulatory bodies and clinical researchers to establish guidelines and best practices for iPSC usage.",
        "mechanism": "Creating a consortium of researchers and clinicians to share data, insights, and resources focused on iPSC standardization.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns with the goals of 'induced pluripotent stem cells (iPSCs)' to advance the understanding and application of iPSCs in regenerative medicine and disease modeling. By collaborating in an open-access, interdisciplinary research consortium, iPSCs can benefit from shared insights and resources, leading to the development of standardized protocols for clinical use. This collaboration also mitigates fears related to the safe and effective application of iPSCs in clinical settings, ensuring that the advancements in Alzheimer's research will contribute positively to the field."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Recruiting researchers in the field of neurology is crucial as they possess the expertise needed to advance the understanding of Alzheimer's disease, contribute to the synthesis of scientific insights, and develop innovative multi-targeted interventions."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments and therapies. Their involvement can help in the development and commercialization of new interventions for Alzheimer's disease."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Involving patients is important to ensure that the research is aligned with the needs and experiences of those affected by Alzheimer's. Their insights can guide the focus of research efforts and ensure the relevance of proposed interventions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) offer a powerful model for understanding the mechanisms of Alzheimer's disease and testing new therapies. Their inclusion can enhance the research consortium's ability to develop and evaluate holistic interventions."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
Resolution structure after processing: {
  "initiator": "Научный журнал",
  "resolution_description": "As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.",
  "new_actor": "Global Alzheimer's AI Research Consortium",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Изучение нейробиологических механизмов заболеваний мозга.",
        "current_action": "Проведение экспериментов и анализ данных.",
        "imposed_goal": "Публикация результатов исследований в 'Научном журнале'.",
        "imposed_action": "Подготовка и отправка статьи для рецензирования.",
        "mechanism": "Предоставление шаблона статьи и инструкции по оформлению для упрощения процесса публикации.",
        "reasoning": "The proposed resolution by 'Научный журнал' offers a collaborative platform that aligns with the desire of 'Исследователи в области нейрологии' to confirm the amyloid hypothesis of Alzheimer's disease while ensuring that research findings are shared and recognized within the scientific community. By participating in an open-access consortium, there is a reduced risk of losing years of research and funding, as it emphasizes transparency and collaboration, which can mitigate fears of reputational damage or funding loss due to data manipulation. Additionally, the focus on interdisciplinary research and AI aligns with the current trends in neuroscience, potentially leading to innovative insights and recognition."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Разработка новых фармацевтических препаратов для улучшения лечения заболеваний.",
        "current_action": "Проведение клинических испытаний и исследований.",
        "imposed_goal": "Увеличение прозрачности процессов разработки и испытаний препаратов.",
        "imposed_action": "Внедрение системы отчетности по всем этапам исследований.",
        "mechanism": "Создание платформы для обмена информацией между фармакологическими компаниями и научными журналами, обеспечивающей доступность данных о клинических испытаниях.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns well with our current desires to develop and patent an effective drug for Alzheimer's disease. By curating an open-access, interdisciplinary research consortium, we can access a wealth of global scientific insights and foster collaboration that may lead to innovative therapeutic approaches. Moreover, the transparency in the development and testing processes will help mitigate our fears of losing investments due to failures or competition, as it promotes accountability and trust in our clinical trials. Engaging with this proposal enhances our potential for success in the Alzheimer's drug development landscape."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Получение качественного медицинского обслуживания",
        "current_action": "Обращение к врачам и участие в медицинских обследованиях",
        "imposed_goal": "Участие в клинических испытаниях для улучшения медицинских исследований",
        "imposed_action": "Регистрация в клинических испытаниях и предоставление необходимых данных о здоровье",
        "mechanism": "Создание платформы для регистрации и информирования пациентов о доступных клинических испытаниях",
        "reasoning": "The proposal by 'Научный журнал' aligns with my desire to live a full life without Alzheimer's symptoms by promoting participation in clinical trials, which can lead to innovative treatments. This approach also addresses my fear of losing memory and independence by fostering a collaborative environment for research that may accelerate the discovery of effective interventions. By registering for clinical trials and contributing health data, I can actively engage in the fight against Alzheimer's, enhancing my prospects for better health outcomes."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To advance the understanding and application of iPSCs in regenerative medicine and disease modeling.",
        "current_action": "Conducting research and experiments to optimize reprogramming techniques and differentiation protocols.",
        "imposed_goal": "To develop a standardized protocol for the safe and effective use of iPSCs in clinical applications.",
        "imposed_action": "Collaborate with regulatory bodies and clinical researchers to establish guidelines and best practices for iPSC usage.",
        "mechanism": "Creating a consortium of researchers and clinicians to share data, insights, and resources focused on iPSC standardization.",
        "reasoning": "The proposed resolution by 'Научный журнал' aligns with the goals of 'induced pluripotent stem cells (iPSCs)' to advance the understanding and application of iPSCs in regenerative medicine and disease modeling. By collaborating in an open-access, interdisciplinary research consortium, iPSCs can benefit from shared insights and resources, leading to the development of standardized protocols for clinical use. This collaboration also mitigates fears related to the safe and effective application of iPSCs in clinical settings, ensuring that the advancements in Alzheimer's research will contribute positively to the field."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Recruiting researchers in the field of neurology is crucial as they possess the expertise needed to advance the understanding of Alzheimer's disease, contribute to the synthesis of scientific insights, and develop innovative multi-targeted interventions."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are essential for translating research findings into viable treatments and therapies. Their involvement can help in the development and commercialization of new interventions for Alzheimer's disease."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Involving patients is important to ensure that the research is aligned with the needs and experiences of those affected by Alzheimer's. Their insights can guide the focus of research efforts and ensure the relevance of proposed interventions."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) offer a powerful model for understanding the mechanisms of Alzheimer's disease and testing new therapies. Their inclusion can enhance the research consortium's ability to develop and evaluate holistic interventions."
    }
  ]
}
Resolution created by Tau protein: As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.
Recruited participants: ['Исследователи в области нейрологии', 'Фармакологические компании', 'induced pluripotent stem cells (iPSCs)', 'Пациенты']
We ask 'Исследователи в области нейрологии' the following: 'As the representative of a being called 'Исследователи в области нейрологии', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Исследователи в области нейрологии' is a participant in the resolution initiated by 'Научный журнал' with the description: 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Tau protein' wants to challenge existing status quo and says to you, 'Исследователи в области нейрологии', the entity you represent, that now you achieve 'Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.' by performing 'Проведение экспериментов по анализу образцов тканей мозга.'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.', you as 'Исследователи в области нейрологии' will be able to achieve 'Разработать терапевтические стратегии для уменьшения уровня тау-белка.' by performing 'Сформировать рабочую группу для разработки новых лекарственных средств.' using 'Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.' that 'Tau protein' will control. Based on 'Исследователи в области нейрологии' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Подтвердить амилоидную гипотезу болезни Альцгеймера и получить признание в научном сообществе. Your current fears: Потерять годы исследований и финансирование, если амилоидная гипотеза окажется неверной, Потерять репутацию и финансирование в случае обнаружения манипуляции данными. Does this proposal seem interesting for you as 'Исследователи в области нейрологии'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Исследователи в области нейрологии agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.",
  "new_actor": "NeuroStabilizer Chaperone System",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.",
        "current_action": "Проведение экспериментов по анализу образцов тканей мозга.",
        "imposed_goal": "Разработать терапевтические стратегии для уменьшения уровня тау-белка.",
        "imposed_action": "Сформировать рабочую группу для разработки новых лекарственных средств.",
        "mechanism": "Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.",
        "reasoning": "The proposal from 'Tau protein' aligns with my current desires to explore new therapeutic strategies for Alzheimer's disease while mitigating my fears of losing years of research and funding. By collaborating on the revolutionary nanoscale molecular chaperone system, I can contribute to a cutting-edge approach that targets the molecular mechanisms of tau protein aggregation, which is critical in Alzheimer's pathology. Additionally, this collaboration offers a platform for interdisciplinary research, potentially validating the amyloid hypothesis while minimizing the risk of reputational damage associated with data manipulation, as the focus shifts to a more comprehensive understanding of the disease."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in the field of neurology are essential for advancing the understanding of tau protein dynamics and the mechanisms underlying Alzheimer's disease. Their expertise will be crucial in designing and validating the nanoscale molecular chaperone system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are vital for translating the proposed solution into viable therapeutic products. Their resources and expertise in drug development will help in the formulation and commercialization of the molecular chaperone system."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used for modeling Alzheimer's disease and testing the efficacy of the proposed therapeutic approach. They provide a powerful platform for studying tau protein behavior in human neuronal cells."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the research and development efforts. Engaging them in the process ensures that the developed solutions are patient-centered and address their needs and concerns effectively."
    }
  ]
}
Исследователи в области нейрологии has moved to a new resolution.
We ask 'Фармакологические компании' the following: 'As the representative of a being called 'Фармакологические компании', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Фармакологические компании' is a participant in the resolution initiated by 'Научный журнал' with the description: 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Tau protein' wants to challenge existing status quo and says to you, 'Фармакологические компании', the entity you represent, that now you achieve 'Develop new pharmacological treatments for neurodegenerative diseases.' by performing 'Conducting clinical trials for existing drug candidates.'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.', you as 'Фармакологические компании' will be able to achieve 'Accelerate the development of therapies targeting Tau protein aggregation.' by performing 'Increase funding and resources towards research specifically focused on Tau protein.' using 'Establish collaboration with research institutions to facilitate knowledge sharing and expedite the drug development process.' that 'Tau protein' will control. Based on 'Фармакологические компании' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Разработать и запатентовать эффективное лекарство от болезни Альцгеймера. Your current fears: Потерять инвестиции в случае неудачи в разработке препарата или появления конкурирующего лечения. Does this proposal seem interesting for you as 'Фармакологические компании'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Фармакологические компании agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.",
  "new_actor": "NeuroStabilizer Chaperone System",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.",
        "current_action": "Проведение экспериментов по анализу образцов тканей мозга.",
        "imposed_goal": "Разработать терапевтические стратегии для уменьшения уровня тау-белка.",
        "imposed_action": "Сформировать рабочую группу для разработки новых лекарственных средств.",
        "mechanism": "Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.",
        "reasoning": "The proposal from 'Tau protein' aligns with my current desires to explore new therapeutic strategies for Alzheimer's disease while mitigating my fears of losing years of research and funding. By collaborating on the revolutionary nanoscale molecular chaperone system, I can contribute to a cutting-edge approach that targets the molecular mechanisms of tau protein aggregation, which is critical in Alzheimer's pathology. Additionally, this collaboration offers a platform for interdisciplinary research, potentially validating the amyloid hypothesis while minimizing the risk of reputational damage associated with data manipulation, as the focus shifts to a more comprehensive understanding of the disease."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological treatments for neurodegenerative diseases.",
        "current_action": "Conducting clinical trials for existing drug candidates.",
        "imposed_goal": "Accelerate the development of therapies targeting Tau protein aggregation.",
        "imposed_action": "Increase funding and resources towards research specifically focused on Tau protein.",
        "mechanism": "Establish collaboration with research institutions to facilitate knowledge sharing and expedite the drug development process.",
        "reasoning": "The proposed resolution by 'Tau protein' aligns with our desire to develop and patent an effective Alzheimer's treatment by focusing on Tau protein aggregation. This approach not only targets the molecular basis of the disease but also provides a strategic avenue for collaboration with research institutions, which can enhance our credibility and mitigate fears of investment loss. By increasing funding and resources towards Tau research, we can potentially accelerate the development of therapies while also positioning ourselves advantageously in the competitive landscape of neurodegenerative treatments."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in the field of neurology are essential for advancing the understanding of tau protein dynamics and the mechanisms underlying Alzheimer's disease. Their expertise will be crucial in designing and validating the nanoscale molecular chaperone system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are vital for translating the proposed solution into viable therapeutic products. Their resources and expertise in drug development will help in the formulation and commercialization of the molecular chaperone system."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used for modeling Alzheimer's disease and testing the efficacy of the proposed therapeutic approach. They provide a powerful platform for studying tau protein behavior in human neuronal cells."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the research and development efforts. Engaging them in the process ensures that the developed solutions are patient-centered and address their needs and concerns effectively."
    }
  ]
}
Фармакологические компании has moved to a new resolution.
We ask 'induced pluripotent stem cells (iPSCs)' the following: 'As the representative of a being called 'induced pluripotent stem cells (iPSCs)', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'induced pluripotent stem cells (iPSCs)' is a participant in the resolution initiated by 'Научный журнал' with the description: 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Tau protein' wants to challenge existing status quo and says to you, 'induced pluripotent stem cells (iPSCs)', the entity you represent, that now you achieve 'To differentiate into specific cell types for regenerative medicine applications.' by performing 'Cultivating and maintaining iPSCs in a pluripotent state in vitro.'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.', you as 'induced pluripotent stem cells (iPSCs)' will be able to achieve 'To enhance the understanding of Tau protein's role in neurodegeneration.' by performing 'To conduct experiments focusing on the differentiation of iPSCs into neurons and studying Tau protein interactions.' using 'Implementing a differentiation protocol that incorporates Tau protein manipulation to observe its effects on neuronal development and function.' that 'Tau protein' will control. Based on 'induced pluripotent stem cells (iPSCs)' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: nan. Your current fears: nan. Does this proposal seem interesting for you as 'induced pluripotent stem cells (iPSCs)'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
induced pluripotent stem cells (iPSCs) agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.",
  "new_actor": "NeuroStabilizer Chaperone System",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.",
        "current_action": "Проведение экспериментов по анализу образцов тканей мозга.",
        "imposed_goal": "Разработать терапевтические стратегии для уменьшения уровня тау-белка.",
        "imposed_action": "Сформировать рабочую группу для разработки новых лекарственных средств.",
        "mechanism": "Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.",
        "reasoning": "The proposal from 'Tau protein' aligns with my current desires to explore new therapeutic strategies for Alzheimer's disease while mitigating my fears of losing years of research and funding. By collaborating on the revolutionary nanoscale molecular chaperone system, I can contribute to a cutting-edge approach that targets the molecular mechanisms of tau protein aggregation, which is critical in Alzheimer's pathology. Additionally, this collaboration offers a platform for interdisciplinary research, potentially validating the amyloid hypothesis while minimizing the risk of reputational damage associated with data manipulation, as the focus shifts to a more comprehensive understanding of the disease."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological treatments for neurodegenerative diseases.",
        "current_action": "Conducting clinical trials for existing drug candidates.",
        "imposed_goal": "Accelerate the development of therapies targeting Tau protein aggregation.",
        "imposed_action": "Increase funding and resources towards research specifically focused on Tau protein.",
        "mechanism": "Establish collaboration with research institutions to facilitate knowledge sharing and expedite the drug development process.",
        "reasoning": "The proposed resolution by 'Tau protein' aligns with our desire to develop and patent an effective Alzheimer's treatment by focusing on Tau protein aggregation. This approach not only targets the molecular basis of the disease but also provides a strategic avenue for collaboration with research institutions, which can enhance our credibility and mitigate fears of investment loss. By increasing funding and resources towards Tau research, we can potentially accelerate the development of therapies while also positioning ourselves advantageously in the competitive landscape of neurodegenerative treatments."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for regenerative medicine applications.",
        "current_action": "Cultivating and maintaining iPSCs in a pluripotent state in vitro.",
        "imposed_goal": "To enhance the understanding of Tau protein's role in neurodegeneration.",
        "imposed_action": "To conduct experiments focusing on the differentiation of iPSCs into neurons and studying Tau protein interactions.",
        "mechanism": "Implementing a differentiation protocol that incorporates Tau protein manipulation to observe its effects on neuronal development and function.",
        "reasoning": "The proposed resolution by Tau protein aligns well with the interests of induced pluripotent stem cells (iPSCs) in enhancing the understanding of neurodegeneration mechanisms. By collaborating on the development of a nanoscale molecular chaperone system to stabilize tau protein and conducting experiments on iPSC-derived neurons, iPSCs can directly contribute to significant advancements in Alzheimer's research. This collaboration not only offers a pathway to achieve scientific goals but also mitigates any fears related to stagnation in research by fostering innovation and interdisciplinary cooperation."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in the field of neurology are essential for advancing the understanding of tau protein dynamics and the mechanisms underlying Alzheimer's disease. Their expertise will be crucial in designing and validating the nanoscale molecular chaperone system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are vital for translating the proposed solution into viable therapeutic products. Their resources and expertise in drug development will help in the formulation and commercialization of the molecular chaperone system."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used for modeling Alzheimer's disease and testing the efficacy of the proposed therapeutic approach. They provide a powerful platform for studying tau protein behavior in human neuronal cells."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the research and development efforts. Engaging them in the process ensures that the developed solutions are patient-centered and address their needs and concerns effectively."
    }
  ]
}
induced pluripotent stem cells (iPSCs) has moved to a new resolution.
We ask 'Пациенты' the following: 'As the representative of a being called 'Пациенты', you have been approached by 'Tau protein' with a resolution to deal with the current controversy 'Понимание и лечение болезни Альцгеймера'. Currently, 'Пациенты' is a participant in the resolution initiated by 'Научный журнал' with the description: 'As 'Научный журнал,' propose a resolution to tackle Alzheimer's disease by curating an open-access, interdisciplinary research consortium that leverages cutting-edge AI to synthesize global scientific insights, fostering unprecedented collaboration and accelerating the discovery of holistic, multi-targeted interventions, thereby reimagining the landscape of Alzheimer's research and treatment through a democratized knowledge platform.'. If you decide to leave this resolution, it may be collapsed due to departure of all participants and you won't be able to get the benefits it provided. 'Tau protein' wants to challenge existing status quo and says to you, 'Пациенты', the entity you represent, that now you achieve 'Manage symptoms and improve quality of life' by performing 'Participating in regular therapy sessions and medication regimen'. However, under the proposed resolution 'As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.', you as 'Пациенты' will be able to achieve 'Engage in a tailored exercise program to enhance cognitive function' by performing 'Attend weekly exercise classes specifically designed for cognitive health' using 'Provide access to specialized trainers and cognitive assessments to track progress' that 'Tau protein' will control. Based on 'Пациенты' desires, fears and underlying interests, make a decision on the new proposed scenario. Your current desires: Жить полноценной жизнью без симптомов болезни Альцгеймера. Your current fears: Потерять память, личность и независимость из-за прогрессирования заболевания. Does this proposal seem interesting for you as 'Пациенты'? In other words, does this proposal benefit your desires and help with mitigating fears? Answer YES, NO, MODIFY_RESOLUTION_TEXT, or MODIFY_PROPOSAL. Provide reasoning for your decision in JSON format: The output should be a markdown code snippet formatted in the following schema, including the leading and trailing "```json" and "```":

```json
{
	"decision": string  // The decision of the participant: YES, NO, MODIFY_RESOLUTION_TEXT, MODIFY_PROPOSAL
	"reasoning": string  // The reasoning behind the participant's decision
}
```.'
Пациенты agreed to participate in the resolution proposed by Tau protein
Updated resolution structure: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.",
  "new_actor": "NeuroStabilizer Chaperone System",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.",
        "current_action": "Проведение экспериментов по анализу образцов тканей мозга.",
        "imposed_goal": "Разработать терапевтические стратегии для уменьшения уровня тау-белка.",
        "imposed_action": "Сформировать рабочую группу для разработки новых лекарственных средств.",
        "mechanism": "Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.",
        "reasoning": "The proposal from 'Tau protein' aligns with my current desires to explore new therapeutic strategies for Alzheimer's disease while mitigating my fears of losing years of research and funding. By collaborating on the revolutionary nanoscale molecular chaperone system, I can contribute to a cutting-edge approach that targets the molecular mechanisms of tau protein aggregation, which is critical in Alzheimer's pathology. Additionally, this collaboration offers a platform for interdisciplinary research, potentially validating the amyloid hypothesis while minimizing the risk of reputational damage associated with data manipulation, as the focus shifts to a more comprehensive understanding of the disease."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological treatments for neurodegenerative diseases.",
        "current_action": "Conducting clinical trials for existing drug candidates.",
        "imposed_goal": "Accelerate the development of therapies targeting Tau protein aggregation.",
        "imposed_action": "Increase funding and resources towards research specifically focused on Tau protein.",
        "mechanism": "Establish collaboration with research institutions to facilitate knowledge sharing and expedite the drug development process.",
        "reasoning": "The proposed resolution by 'Tau protein' aligns with our desire to develop and patent an effective Alzheimer's treatment by focusing on Tau protein aggregation. This approach not only targets the molecular basis of the disease but also provides a strategic avenue for collaboration with research institutions, which can enhance our credibility and mitigate fears of investment loss. By increasing funding and resources towards Tau research, we can potentially accelerate the development of therapies while also positioning ourselves advantageously in the competitive landscape of neurodegenerative treatments."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for regenerative medicine applications.",
        "current_action": "Cultivating and maintaining iPSCs in a pluripotent state in vitro.",
        "imposed_goal": "To enhance the understanding of Tau protein's role in neurodegeneration.",
        "imposed_action": "To conduct experiments focusing on the differentiation of iPSCs into neurons and studying Tau protein interactions.",
        "mechanism": "Implementing a differentiation protocol that incorporates Tau protein manipulation to observe its effects on neuronal development and function.",
        "reasoning": "The proposed resolution by Tau protein aligns well with the interests of induced pluripotent stem cells (iPSCs) in enhancing the understanding of neurodegeneration mechanisms. By collaborating on the development of a nanoscale molecular chaperone system to stabilize tau protein and conducting experiments on iPSC-derived neurons, iPSCs can directly contribute to significant advancements in Alzheimer's research. This collaboration not only offers a pathway to achieve scientific goals but also mitigates any fears related to stagnation in research by fostering innovation and interdisciplinary cooperation."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Manage symptoms and improve quality of life",
        "current_action": "Participating in regular therapy sessions and medication regimen",
        "imposed_goal": "Engage in a tailored exercise program to enhance cognitive function",
        "imposed_action": "Attend weekly exercise classes specifically designed for cognitive health",
        "mechanism": "Provide access to specialized trainers and cognitive assessments to track progress",
        "reasoning": "The proposal by 'Tau protein' directly addresses my desire to live a full life without Alzheimer's symptoms by offering a method to target the molecular causes of the disease. Additionally, the opportunity to engage in a tailored exercise program designed to enhance cognitive function aligns with my interests in maintaining my independence and cognitive health. This approach not only mitigates my fears of losing memory and identity but also provides a proactive framework for improving quality of life."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in the field of neurology are essential for advancing the understanding of tau protein dynamics and the mechanisms underlying Alzheimer's disease. Their expertise will be crucial in designing and validating the nanoscale molecular chaperone system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are vital for translating the proposed solution into viable therapeutic products. Their resources and expertise in drug development will help in the formulation and commercialization of the molecular chaperone system."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used for modeling Alzheimer's disease and testing the efficacy of the proposed therapeutic approach. They provide a powerful platform for studying tau protein behavior in human neuronal cells."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the research and development efforts. Engaging them in the process ensures that the developed solutions are patient-centered and address their needs and concerns effectively."
    }
  ]
}
Пациенты has moved to a new resolution.
Resolution structure after processing: {
  "initiator": "Tau protein",
  "resolution_description": "As 'Tau protein,' propose a resolution to tackle Alzheimer's disease by developing a revolutionary nanoscale molecular chaperone system that selectively stabilizes tau protein conformations, preventing pathological aggregation and enabling the restoration of normal neuronal function, thereby offering a groundbreaking approach that directly targets the molecular underpinnings of disease progression and redefines therapeutic strategies through precision protein dynamics control.",
  "new_actor": "NeuroStabilizer Chaperone System",
  "participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "agreement_structure": {
        "current_goal": "Исследовать механизмы накопления и агрегации тау-белка в нейронных клетках.",
        "current_action": "Проведение экспериментов по анализу образцов тканей мозга.",
        "imposed_goal": "Разработать терапевтические стратегии для уменьшения уровня тау-белка.",
        "imposed_action": "Сформировать рабочую группу для разработки новых лекарственных средств.",
        "mechanism": "Создание совместного исследовательского проекта с участием различных лабораторий и клиник для обмена данными и ресурсами.",
        "reasoning": "The proposal from 'Tau protein' aligns with my current desires to explore new therapeutic strategies for Alzheimer's disease while mitigating my fears of losing years of research and funding. By collaborating on the revolutionary nanoscale molecular chaperone system, I can contribute to a cutting-edge approach that targets the molecular mechanisms of tau protein aggregation, which is critical in Alzheimer's pathology. Additionally, this collaboration offers a platform for interdisciplinary research, potentially validating the amyloid hypothesis while minimizing the risk of reputational damage associated with data manipulation, as the focus shifts to a more comprehensive understanding of the disease."
      }
    },
    {
      "participant": "Фармакологические компании",
      "agreement_structure": {
        "current_goal": "Develop new pharmacological treatments for neurodegenerative diseases.",
        "current_action": "Conducting clinical trials for existing drug candidates.",
        "imposed_goal": "Accelerate the development of therapies targeting Tau protein aggregation.",
        "imposed_action": "Increase funding and resources towards research specifically focused on Tau protein.",
        "mechanism": "Establish collaboration with research institutions to facilitate knowledge sharing and expedite the drug development process.",
        "reasoning": "The proposed resolution by 'Tau protein' aligns with our desire to develop and patent an effective Alzheimer's treatment by focusing on Tau protein aggregation. This approach not only targets the molecular basis of the disease but also provides a strategic avenue for collaboration with research institutions, which can enhance our credibility and mitigate fears of investment loss. By increasing funding and resources towards Tau research, we can potentially accelerate the development of therapies while also positioning ourselves advantageously in the competitive landscape of neurodegenerative treatments."
      }
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "agreement_structure": {
        "current_goal": "To differentiate into specific cell types for regenerative medicine applications.",
        "current_action": "Cultivating and maintaining iPSCs in a pluripotent state in vitro.",
        "imposed_goal": "To enhance the understanding of Tau protein's role in neurodegeneration.",
        "imposed_action": "To conduct experiments focusing on the differentiation of iPSCs into neurons and studying Tau protein interactions.",
        "mechanism": "Implementing a differentiation protocol that incorporates Tau protein manipulation to observe its effects on neuronal development and function.",
        "reasoning": "The proposed resolution by Tau protein aligns well with the interests of induced pluripotent stem cells (iPSCs) in enhancing the understanding of neurodegeneration mechanisms. By collaborating on the development of a nanoscale molecular chaperone system to stabilize tau protein and conducting experiments on iPSC-derived neurons, iPSCs can directly contribute to significant advancements in Alzheimer's research. This collaboration not only offers a pathway to achieve scientific goals but also mitigates any fears related to stagnation in research by fostering innovation and interdisciplinary cooperation."
      }
    },
    {
      "participant": "Пациенты",
      "agreement_structure": {
        "current_goal": "Manage symptoms and improve quality of life",
        "current_action": "Participating in regular therapy sessions and medication regimen",
        "imposed_goal": "Engage in a tailored exercise program to enhance cognitive function",
        "imposed_action": "Attend weekly exercise classes specifically designed for cognitive health",
        "mechanism": "Provide access to specialized trainers and cognitive assessments to track progress",
        "reasoning": "The proposal by 'Tau protein' directly addresses my desire to live a full life without Alzheimer's symptoms by offering a method to target the molecular causes of the disease. Additionally, the opportunity to engage in a tailored exercise program designed to enhance cognitive function aligns with my interests in maintaining my independence and cognitive health. This approach not only mitigates my fears of losing memory and identity but also provides a proactive framework for improving quality of life."
      }
    }
  ],
  "required_participants": [
    {
      "participant": "Исследователи в области нейрологии",
      "reasoning": "Researchers in the field of neurology are essential for advancing the understanding of tau protein dynamics and the mechanisms underlying Alzheimer's disease. Their expertise will be crucial in designing and validating the nanoscale molecular chaperone system."
    },
    {
      "participant": "Фармакологические компании",
      "reasoning": "Pharmaceutical companies are vital for translating the proposed solution into viable therapeutic products. Their resources and expertise in drug development will help in the formulation and commercialization of the molecular chaperone system."
    },
    {
      "participant": "induced pluripotent stem cells (iPSCs)",
      "reasoning": "Induced pluripotent stem cells (iPSCs) can be used for modeling Alzheimer's disease and testing the efficacy of the proposed therapeutic approach. They provide a powerful platform for studying tau protein behavior in human neuronal cells."
    },
    {
      "participant": "Пациенты",
      "reasoning": "Patients are the ultimate beneficiaries of the research and development efforts. Engaging them in the process ensures that the developed solutions are patient-centered and address their needs and concerns effectively."
    }
  ]
}
